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ABSTRACT

Role of long chain free fatty acid receptors in the
regulation of brain-derived neurotrophic factor levels
in the enteric glial and endocrine cells
Reem M Alkahtani

A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2016

Directors: S. Murthy Karnam, Ph.D., and John R. Grider, PhD
Professors in the Department of Physiology and Biophysics

Recent deorphanization of several G-protein-coupled receptors (GPRs) as
endogenous receptors for free fatty acids (FFAs) has increased our understanding of
these nutrients as signaling molecules and the integral role of gut microbiota in the
regulation of host defense mechanisms, energy metabolism, gastrointestinal motility and
secretion. There are five distinct FFA receptors (FFRAs: FFAR1, FFAR2, FFAR3, FFAR4
and GPR84) that differ in molecular structure, ligand specificity, expression pattern, and
functional properties. FFARs are grouped according to the chain length of FFAs that
activate each FFAR.
Enteric glial cells and enteroendocrine cells play a pivotal role in the secretion of
gliotransmitters and peptide hormones, respectively, in response to specific stimuli.
xv

Neurotrophins such as brain-derived neurotrophic factor (BDNF) are essential for the
development and integrity of enteric nervous system in the gut and play an important role
in the regulation of gastrointestinal functions including motility and secretion.
The aim of this study was to identify the expression of FFARs in enteric glial cells
and endocrine cells and determine the effects of fatty acids in the regulation of BDNF
levels. Expression studies of FFARs by quantitative PCR, western blot and
Immunohistochemistry from glial cells and enteroendocrine cells (STC-1 cells)
demonstrated predominant expression of FFAR4 in STC-1 cells and predominant
expression of FFAR1 in glial cells. Both FFAR1 and FFAR4 are activated by long-chain
fatty acid.
Activation of specific G protein(s) coupled to FFAR1 and FFAR4 and signaling
pathways downstream of G proteins in response to the endogenous long chain fatty acid,
linolenic acid (100 µM), demonstrated both FFAR1 and FFAR4 are coupled to Gαq and
stimulation of PLC-β/IP3/ Ca2+ pathway. In enteroendocrine cells (STC-1) long chain fatty
acids preferentially activate FFAR4, whereas in glial cells long chain fatty acids
preferentially activate FFAR1. Furthermore, measurement of changes in BDNF levels in
response to linolenic acid by immunocytochemistry and enzyme-linked immunosorbent
assay (ELISA) demonstrated that in STC-1 cells, long chain fatty acids increased BDNF
content via FFAR4, whereas in glial cells they increased BDNF content via FFAR1. The
present study shed light on the expression and physiological role of long chain fatty acids
and FFARs in the regulation of BDNF levels, and thus, gastrointestinal functions.

xvi

INTRORDUCTION AND BACKGROUND

1. Introduction

The gastrointestinal tract is a long muscular tube; approximately 6.5 meters (20
feet) long, and is responsible for the digestion, absorption of nutrients, and expulsion of
waste. The ingested food breaks down into small molecules and the movement of
nutrients, water, and electrolytes from the lumen of the intestine into the blood require the
major activities of gastrointestinal tract to be served. First of these is the gut motility, which
is determined by the patterns of contraction and relaxation of the circular and longitudinal
muscle layers to mix chyme with digestive enzymes and propel ingested food from the
mouth toward the rectum. Second, the secretions of additional fluids, enzymes and mucus
into the lumen from salivary glands, the cells of gastric mucosa, pancreas and liver are
regulated. Motility and secretion further aid in digestion and absorption, which are the
ultimate functions of the gastrointestinal tract.

I.1 The Structure of The Gastrointestinal Tract Wall.
The digestive system is characterized by a wall contains four layers, from inside
lining of the tract to the outside lining: the mucosa is the innermost layer, underneath is
submucosa which is a loose connective tissue layer with blood vessels, nerves, lymphatic
and secreting gland. The submucosa is then followed by the muscular propria which
contains two layers of the smooth muscle; circular smooth muscle cells is the inner layer,
1

and the outer layer is longitudinal smooth muscle cells. The main function of smooth
muscle of the gut is to mix and propel intraluminal contents allowing effective digestion of
food, and absorption of nutrients. Finally the outermost layer – the serosa, is a serous
membrane that covers the muscularis externa and comprises a loose connective tissue
that is covered by the visceral peritoneum that contains blood vessels, lymphatic, and
nerves.
1.2 Enteric Nervous System
The human enteric nervous system (ENS) contains about 150 million nerve cells,
comprising the largest division of the autonomic nervous system (Langley 1921). ENS
provides confined neural control of the gastrointestinal tract and is essential in
coordinating the digestive and defensive functions in the gut. A characteristic of ENS is
that the nerve cell bodies located within the wall of the gut are organized into two
ganglionated plexuses and nerve fibers throughout the external muscle layers,
submucosa, and mucosa. The Myenteric plexus is located between the outer longitudinal
and the inner circular smooth muscle layers of the muscularis externa and its neurons
play a role in the gut motility. The submucosal plexus is located between the circular
muscle layer and the muscularis mucosa and its neurons are involved in mucosal
function, secretion, blood flow, and barrier function. Neurons of the ENS are supported
by unique peripheral glial cells called enteric glia (Grundy and Brooks 1996). There are
different classes of neurons in the ENS; motor neurons, classified as excitatory motor
neurons that release acetylcholine or substance P as neurotransmitter or inhibitory motor
neurons that release nitric oxide (NO) or vasoactive intestinal peptide (VIP) as transmitter.
Both motor neurons innervate the muscle layer in the gut (Harmer, Fahrenkrug et al.
2

2012). In addition to motor neurons, there are sensory neurons, which have been
classified as Dogiel type II neurons, which are characterized by multiple processes that
via a complex of neuronal network that includs synaptic connections with interneurons,
motor neurons and other sensory neurons (Grundy and Brooks 1996).
1.3 Cells in the Gastrointestinal Tract.
There are multiple type of cells that line the gastrointestinal tract wall from the
stomach to the anal sphincter. In the mucosal layer there are; enteroendocrine cells,
brush cells, goblet cells, and paneth cells. Inflammatory cells are in the lamina propria,
and in the muscularis externa there are smooth muscle cells, which also includes
interstitial cells of Cajal, enteric neurons and glial cells. Each of them has different
function.
For example, the goblet cells are specialized cells scattered in the epithelium of the small
intestine and colon. They are interposed between enterocytes and secret mucins which
play role in mucosa curing and protection. Whereas, Paneth cells, are known for their
location at the ends of the intestinal crypt. They play a role in the innate immunity system
regulation of lamina microflora in the small intestine by secreting anti-microbial peptides
into the crypt lumen, thereby providing protection for the stem cells that line the crypt
walls. Other cells in mucosa such as brush cells are similar to other cells and they are
specialized epithelial cells that are scattered within the epithelial lining of the
gastrointestinal tract (Moore, B.A et al 2000; Kieta, A.V et al 2010). Moreover, smooth
muscle cells in the gut are spindle shape cells, that contain actin and myosin, and are
electrically coupled by gap junction for generating contractions. Also, interstitial cells of
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Cajal (ICCs) are the gut pacemaker cells that creates electrical slow waves leading to
smooth muscle contraction (Takaki M 2003).
However, two of the main cell types that have gained more attention recently are
enteric glial cells and enteroendocrine cells.

2. Enteric Glial Cells
2.1 Historical Perspective on Enteric Glia Cells. More than 115 years ago, the
first known description of the enteric glia was demonstrated by Dogiel in 1899. Yet, enteric
glia were not clearly illustrated until just over 35 years ago when Giorgio Gabella for the
first time addresed the structural relationship between enteric neurons and glia in enteric
nervous system. He identified them as a unique class of cells and were name enteric glia
cell (Gabella, 1981). The word “glia” derives from the Greek word for “glue”. They were
seen as a mere packing substance holding the enteric nervous system together (A Ruhl
2005).
The enteric glial cells are small cells with irregular stellate shape cell bodies and
highly branched processes that extend from the cell body interposed throughout the
neuropil. In addition, the composition of gliofilaments in enteric glia is predominantly
composed of glial fibrillary acidic protein (GFAP) and vimentin (Jessen and Mirsky, 1983).
There are four major types of enteric glia: 1) type I “protoplasmic” enteric gliocytes,
the star-shaped enteric glia within enteric ganglia, 2) type II “fibrous” enteric gliocytes, the
elongated glia within interganglionic fiber tracts, 3) type III “mucosal” enteric gliocytes
associated with nerve fibers and epithelial cells at the level of the mucosa, and 4) type IV
4

“intramuscular” enteric gliocytes, the elongated glia associated with nerve fibers scattered
between smooth muscle cells. (Liu et al, 2013).
2.2 Function Roles of Enteric Glia. For a long time, enteric glial cells were
believed to play role mainly as support cells for neurons. Over the past five years the
importance of glial cells in the gut has been studied and this dogma has been gradually
abandoned. Enteric glia cells are actively involved in modulating gut processes. They are
a significant regulator of gut barrier maintenance which is required to protect the gut
lumen from the invasion by bacteria, viruses or foreign substances. Dr. Brian Gulbransen
in his enteric glia chapter remark that Type III enteric glial cells in the intestinal mucosa
have an important role in maintaining the integrity of the mucosal barrier of the gut (A
Ruhl 2005). Type I and Type II enteric gliocytes are important in the support of enteric
neurons,

they

are

involved

in

homeostatic

control

that

maintain

enteric

neurotransmission. (Gulbransen and Sharkey, 2012). Additionally, enteric glia actively is
involved in the regulation of neurotransmission and gliotransmission by participating in
neurotransmitter synthesis or inactivation, which influence the gut function. Enteric glial
cells may also contribute in the regulation of intestinal epithelial function; cell bodies and
processes of enteric glial cells extend to the mucosal plexus and come in close contact
with the epithelial cell layer.
There are some neurotrophins as well as neurotransmitters that are produced from
enteric glial cells, such as, nerve growth factor (NGF), and glial cell-derived neurotrophic
factor (GDNF) (Boyen et al, 2006; Korsak et al. 2012). The most well characterized
neurotransmitter released from enteric glial cells is ATP, which has a potential role to
trigger intracellular calcium waves and influence adjacent neurons, thus modulating
5

enteric neurotransmission (Zhang et al. 2007). Enteric glial cells also release nitric oxide
(NO), the inhibitory neurotransmitter that has a physiological role in modulating epithelial
ion transport (MacEachern et al. 2011 and Esposito et al, 2013).
The role of enteric neurons in the regulation of gastrointestinal function is well
known, however the role of enteric glial cells in the regulation of gastrointestinal function
has only recently started to be elucidated. Moreover, the current knowledge about enteric
glial in the human gut health and disease is rather poor.

3. Enteroendocrine Cells
3.1 Characteristics of the Enteroendocrine cells.

The

gastrointestinal

tract

is

profoundly involved in the control of metabolism and motility via peptide hormones
secreted from enteroendocrine cells scattered throughout the gut mucosa (Engelstoft MS,
et al 2013). The endocrine system produces more than 20 different hormones from at
least 10 distinct enteroendocrine cells that mediate effects through neuronal, auto, and
paracrine mechanism.
Enteroendocrine cells constitute the largest endocrine organ of the human body,
they are a group of specialized epithelial cells distributed among mucosal cells of the
gastrointestinal tract, that represent less than 1% of the mucosal cell population (Tongzhi
Wu et al. 2013). Enteroendocrine cells might be the first level of integration of information
from the gut lumen, which act as specialized transducer of luminal factors, producing and
secreting a variety of hormones or/and signaling molecules including: motilin, ghrelin,
gastrin, somatostatin, cholecystokinin (CCK), glucose-dependent insulinotropic peptide
6

(GIP), glucagon-like peptide-1 (GLP-1), and peptide YY (PYY). Each one of these
hormones are released from different type of enteroendocrine cells which are differentially
distributed in the gut. Such as I-cells and K-cells, that release cholecystokinin and
glucose-dependent insulinotropic peptide, respectively, predominate in the proximal small
intestine. Whereas, L- cells are present in highest concentration in the distal small
intestine and colon which are responsible in glucagon-like peptide-1 (GLP-1) and peptide
YY (PYY) release (Tongzhi Wu et al 2013).
3.2 Classification of The Enteroendocrine Cells. There are two types of
enteroendocrine cells that are observed in the gut. The first is an open cell type. In most
of enteroendocrine cells exhibit the characteristic of open type structure, as they have
microvilli extending to the gut luminal surface. Microvilli are directly in contact with gut
lumen, providing the ability to sense luminal contents or increased the level of absorbed
substances across the epithelial layer (Duca FA and Lam TK 2014). In addition to open
cell type, there are closed cells that do not reach the lumen. Such as, ghrelin- secreting
cells that do not come into contact with the gastric lumen (Parker HE et al. 2008).
Moreover, enteroendocrine cells are known as chemoreceptors that sense ingested
substances (nutrient and non-nutrients). Upon activation they induce changes in
gastrointestinal function and food intake through the release of signaling substances
acting on a variety of targets locally or at a distance.
Hormones or peptides released from enteroendocrine cells possibly will
communicate through paracrine fashion by interacting locally on specific receptors on
vagal nerves or enteric neurons to activate afferent terminals or other cells. They can also
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act in an endocrine fashion through the intestinal capillaries and the lymphatic system
and on specific receptors located on more distant targets.
3.3 Function Roles of Enteroendocrine Cells Secretion. The enteroendocrine
cells are the first level of integration of information from the gut and are responsible for
secreting an array of gut hormones that induce changes in gastrointestinal physiological
function through the release of signaling molecules. The gut peptides released from
enteroendocrine cells play a pivotal role in the regulation of multiple physiological
responses including gastrointestinal motility and secretion, glucose level control, food
intake, and gastric emptying. K cells secret glucose-dependent insulinotropic peptide, an
incretin hormone, which stimulates glucose induced insulin release. I cells secrets
cholecystokinin, which “was the first GI peptide for which a satiating effect was described”
(Mansouri A 2014) by acting as a hunger suppressant. CCK mediates digestion in the
small intestine by slowing gastric emptying. L cells secrets glucagon-like peptide-1, an
incretin hormone. It plays an important role in promoting glucose homeostasis by
augmenting insulin secretion, suppressing glucagon release and slowing gastric
emptying, as well as by reducing food intake. In addition to glucagon like peptide-1, L
cells secret peptide YY hormone that has physiological function in inhibiting the gastric
motility (Parker HE et al. 2014).

4.1 Neurotrophins
Originating from the greek words (trophe) meaning nourishment, neurotrophins are
target-derived growth factors that regulate the survival, phenotypic differentiation, and
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promote growth of axonal neurons in the central, peripheral, and enteric nerves system.
There are four members of neurotrophic family; Nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), neurotrophin-3 NT3 and neurotrophin-4 NT4 (Prakash et al
2010).
4.2 Brain-derived Neurotrophic Factor. Brain derived neurotrophic factor was
the second discovered member of neurotrophins family of growth factor, which regulates
the neuronal differentiation, migration, synaptic function. It also plays an important role in
memory processes. Physiological functions of BDNF are initiated by binding to two
classes of cell surface receptors; the first class is tropomyosin-related kinase (TrkB)
receptor that binds to the BDNF with high affinity, the second class is the panneurotrophin receptor (p75NTR) which binds to the BDNF with low affinity (Binder and
Scharfman 2004) .
4.3 Synthesis of BDNF. BDNF is synthesized as pre-pro-BDNF. On the rough
endoplasmic reticulum (ER), the pre-BDNF single peptide is cleaved into pro-BDNF that
is packaged in the Golgi, transported to the nerve terminal, stored in presynaptic vesicles
and secreted from terminals in a stimulus-dependent manner. Neurotrophin-induced
BDNF effects involve activation of TrkB that mediate PLCγ1 activation and IP3-induced
mobilization of Ca+2 from the endoplasmic reticulum. Increase in intracellular Calcium
causes secretion of BDNF (Hasbi A et al 2009).
Changes in BDNF components are associated with pathological conditions. The
high BDNF level is related to lower stroke rate, Alzheimer’s, Parkinson’s disease, and
depression (Hashimoto et al 2005).
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4.4 BDNF in the Gut. In the mature gastrointestinal tract of several species, such
as human, rat, and mouse, the presence of BDNF and its receptors has been
demonstrated. Expression of BDNF has been identified in enteroendocrine cells and
enteric glial cells in the gut. Recent studies from Grider, et al 2006 have shown that
stimulation of mucosa induces the release of BDNF which augments the release of 5-HT
and calcitonin gene related peptide (CGRP), thus, enhancing the peristaltic reflex and
gastrointestinal motility (Grider et al 2006).
Moreover, BDNF has an excitatory effect on colon, increase in the rate of colonic
pellet propulsion has been observed. In human, BDNF increases gut motility, diarrhea,
and bowel urgency. Changes in BDNF components in the gut are associated with
inflammatory bowel disease, and it has been reported that increased BDNF levels were
associated with ulcerative colitis (Massa SM et al 2010).

5.1 Free Fatty Acids and Their Receptors
Free fatty acids are essential nutrients that have very important function as a
source of energy, structural contribution to cellular components, and maintaining
homeostasis under physiological and pathophysiological states. This is due to the
contribution to coordinating expression of proteins involved in lipid uptake, synthesis,
transport storage and degradation (Nilsson NE et al 2003). There are two types of fatty
acids based on their formation: short chain free fatty acids that are primarily produced
through the fermentation of indigestible fiber such as carbohydrates, oligosaccharides
and resistant starch by anaerobic gut flora (Paul LE et al. 2003). The second type of fatty

10

acids have longer-chain fatty acids. They are the products of dietary intake, adipose
recycling, and hepatic turnover of neutral fats and phospholipids (Wong JM et al. 2006).
Also FFAs are categorized by the length of their carbon chain; short-chain fatty acids with
carbon length less than 6 carbons, medium-chain fatty acid with carbon length between
6-12 carbons, and long-chain fatty acids have more than 14 carbons.
The major component of short chain fatty acids in the human colon contains
acetate (C2), propionate (C3), and butyrate (C4) with ratio of almost 3: 1: 1 respectively
(Savage DC 1988). The total concentration of the short chain fatty acid is about 100 mM
in the lumen of mammalian colon, yet the precise ratio is dependent on species and diet.
In past decade, it has been reported that the sensor of free fatty acids are nuclear
receptors, including peroxisome proliferator-activated receptor (PPARs) (Chawla A et al.
2001). However, the free fatty acid effects on some biological processes have been
suggested to involve cell surface receptors. Recent data have recognized free fatty acids as

endogenous agonists for a small family of G-protein coupled receptors.
5.2 Free Fatty Acids Receptors (FFARs) Five different membrane-bound free
fatty acid receptors have been recently identified upon successful deorphanization
strategy. The free fatty acids receptor are G protein-coupled receptor (GPCRs) activated
by free fatty acids. In the gastrointestinal tract these receptors for free fatty acids serve
as nutrient sensor and differ in their ligand specificity, expression pattern, and functional
properties (Kotarsky K et al. 2003). Short chain fatty acids (six or less carbon chain length)
activate FFAR2, and FFAR3. GPR84 is activated by medium-chain free fatty acids,
whereas both saturated and unsaturated medium- and long chain fatty acids activate
FFAR1 and FFAR4 (Briscoe CP et al, 2003; Brown AJ et al. 2003; and Itoh Y et al. 2003).
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5.3 FFAR1

FFAR1 is a G protein-coupled receptor recognized to be activated by medium to
long chain saturated and unsaturated free fatty acids. The Briscoe group has reported
that several free fatty acids work as agonists to FFAR1 in the micromolar concentration
range. The potency of saturated free fatty acids to activate FFAR1 depends on their
carbon chain length. However, the length of the carbon chain or the saturation degree
doesn’t correlate with the potencies of the unsaturated fatty acids (Briscoe CP et al, 2003;
Brown AJ et al. 2003; Itoh Y et al. 2003).
5.3.1 Ligands. As mention previously, three separate groups reported that
medium to long chain fatty acids activated FFAR1. The rank order of the agonists display
most potency were as follows: docosahexaenoic acids (DHA, C22:6) > alpha-linolenic
acid (C18:3) = oleic acid (C18:1) > palmitic acid (C16) and pentadeconic acid (C15). In
addition to the natural ligands, several pharmacological studies reported novel series of
FFAR1 agonists. GW9508 is a FFAR1 selective ligand used in many studies with 100fold more potent than at FFAR4 (Hara T et al 2013). The agonist activity of free fatty acids
ligands has been evaluated by intracellular calcium response. Besides GW9508, Medica
16, NCG75, PRARγ (thiazolidinedione) and TAK-857 have been reported as
pharmacological ligands that activate FFAR1 (Hara T et al. 2011; Fukunaga S et al. 2006).
5.3.2 Expression. FFAR1 expression was analysed by reverse-transcription
polymerase chain reaction (RT-PCR), immunohistochemistry, and in situ hybridization
techniques and revealed high level of FFAR1 expression in various tissues. Ubiquitous
distribution of FFAR1 but with the highest expression was observed in the brain, then in
the pancreas (Briscoe 2003). Moreover, FFAR1 mRNA has been detected in mammary
12

gland such as bovine mammary epithelial gland.

In particular FFAR1 shows high

expression in the β cells (insulin producing pancreatic islet cells). Also, expression of the
FFAR1 protein has been reported in the endocrine cells of gastrointestinal tract (Edfalk
et al. 2008).
5.3.3 Signal Transduction and Physiological Function. FFAR1 plays an
important physiological role in the intestine by contributing to insulin secretion. It has been
reported that activation of FFAR1 by medium to long chain fatty acids promotes glucosestimulated insulin secretion (GSIS) from pancreatic β cells. Various reports have
confirmed that FFAR1 mediates the increase in intracellular calcium and the insulin
secretion coupled to Gαq protein leading to activation of phospholipase C (PLC) and
subsequent increase in the intracellular calcium concentration in β cells, which results in
mobilization of calcium from endoplasmic reticulum (ER) leading to calcium influx through
voltage-dependent L-type Ca2+ channel (VLTCC).
Furthermore, activation of FFAR1 on endocrine cells of the gastrointestinal tract
enhances insulin secretion indirectly through the release of incretin hormones, since
receptors for glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) are expressed in pancreatic β cells (Itoh et al. 2003; Edfalk 2008).
Moreover, Efdalk et al 2008, have shown that oral fat diet administration to FFAR1-null
mice results in an impaired secretion of both peptides; GLP-1 and GIP with a decrease in
insulin secretion (Steneberg P et al. 2005; Shapiro H et al. 2005; Fujiwara K et al. 2005).
Similarly, loss of the FFAR1 function via free fatty acids receptor 1 small interfering
RNA (siRNA) treatment suppresses the insulin secretion in response to free fatty acid
stimulation. Also, it has been reported that fatty acid stimulated-induced insulin secretion
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was significantly decreased in FFAR1 knock out mice (Hara T et al. 2013). These reports
suggest that FFAR1 plays a crucial role in the mechanism involved in the development of
obesity and type 2 diabetes (Steneberg P et al. 2005; Shapiro H et al. 2005).
5.4.1 FFAR2
FFAR2 is a deorphanized G protein coupled receptor that has been identified to
be activated with short chain free fatty acids for the first time in 2003. Two separate
groups (Brown et al. 2003 and Nilsson et al. 2003) have demonstrated during ligand
fishing that FFAR2 was activated by the short chain fatty acid acetate.
5.4.2 Ligands. Short chain fatty acid (SCFAs) with carbon length less than six
carbons such as formate, acetate, propionate, butyrate, and pentanoate have been
shown to be the endogenous agonists of FFAR2. However, this receptor shows
differences in ligand specificity and tissue localization from FFAR3. The rank order of
ligand potencies for FFAR2 activation was as follow: acetate = propionate > butyrate
(Brown et al. 2003, Poul et al. 2003, and Nilsson et al. 2003). Recently it has been
reported that different species show differences in the rank potency of short chain fatty
acid ligands (Hansen et al 2012).
5.4.3 Expression. FFAR2 has been shown to be expressed in various tissues,
in particular fat stores, inflammatory cells and the gastrointestinal tract (Hong 2005).
Since short chain fatty acids are highly concentrated in the distal gastrointestinal tract it
has been reported that FFAR2 is found in mucosal cells of the ileum and large intestine.
Their pattern of expression is variable along the intestine and perhaps among various
species (Tazo H et al. 2009 and Ulven T 2012).
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5.4.4 Signal Transduction and Physiological Function. Several reports have
confirmed that stimulation of FFAR2 by short chain fatty acids lead to inhibition of cAMP
production. Even though FFAR2 and FFAR3 have similar endogenous ligands, their Gprotein signaling mechanisms are different. Both the Gq pathway and the pertussis toxin
sensitive Gi/o pathway are activated by FFAR2 (le Poul et al 2003).
As mention above, FFAR2 is highly expressed in adipose tissue. A series of
studies has been made to understand the role of FFAR2 in adipocytes by Hang et al.
There results suggested that activation of FFAR2 by short chain fatty acids inhibits
lipolysis, and increases adipogenesis.
Moreover, the Karaki group in 2008, by using reverse transcription polymerase
chain reaction (RT-PCR) and immunohistochemistry detected colocalization of the
FFAR2 with PYY (peptide YY) in mucosal epithelium and mast cells. These discoveries
elucidate the crucial role of FFAR2 in the gastrointestinal tract. Prior studies have reported
that short chain fatty acids stimulate the release of 5-HT and PYY from the ileum and
colon (Karaki et al 2006). This led to the hypothesis that FFAR2 might contribute to these
pathways as transduces between nutrient stimuli and satiety mediator release in distal
gastrointestinal tract. Eventually FFAR2 might be a putative transducer of free fatty acid
stimuli and have a therapeutic use in the treatment of numerous metabolic disorders,
including diabetes and obesity (Samuel BS et al. 2008).
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5.5.1 FFAR3
FFAR3 is a deorphanized G protein coupled receptor reported for the first time in
2003 by Brown et al. Similar to FFAR2, short chain fatty acids with carbon length less
than six carbons have been demonstrated to be the endogenous agonist of FFAR3
(Tazoe H et al. 2009).
5.5.2 Ligands. FFAR3 was activated by short chain fatty acids. As mention in the
previous section, the rank order of potencies with respect to activation of FFAR2 was as
follow: acetate = propionate > butyrate. Whereas, that of FFAR3 was as follow: propionate
> butyrate > acetate. Due to the low potency level of acetate in FFAR3 it has been used
to distinguish between FFAR3 and FFAR2. Moreover, there are several pharmacological
compound reported as FFAR3 agonist, such as, compound 5 (Leonard TW et al 2006).
5.5.3 Expression. The initial expression studies using reverse transcriptase
polymerase chain reaction detected highest levels of FFAR3 mRNA expression in the
adipose tissue across a panel of human tissue (Xiong et al. 2004). In addition to its extragastrointestinal localization, FFAR3 has been detected in the small and the large
intestinal mucosa (Cohen P et al. 2001; Latour MG et al 2007). The FFAR3 expression
also was found in the enteroendocrine cells of the distal small intestine (ileum) and the
(proximal) colon (Karaki et al. 2006).
5.54 Signal Transduction and Physiological Function. Various reports have
confirmed that FFAR3 mediated the release of intracellular calcium and the
phosphorylation of ERK1/2 (Le Poul et al 2003). Pertussis toxin treatment completely
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abolished the intracellular calcium and ERK1 phosphorylation. Therefore, it has been
suggested that the signaling mechanism activated by FFAR3 was coupled to Gi/o.
The analysis of FFAR3-deficient mice demonstrated that FFAR3 deficiency is
associated with reduction of PYY (peptide YY) expression, increased intestinal transit
rate, and reduction of extraction of energy obtained from short chain free fatty acids that
are produced by the microbial fermentation of indigestible dietary polysaccharide (Samuel
BS et al. 2008). These results suggest that FFAR3 regulates host energy balance through
mechanisms that are dependent upon the microbiota (Xiong Y et al. 2004; Samuel BS et
al. 2008; Karaki S et al. 2006).
Moreover, it has been reported that short chain fatty acids enhance leptin
production by adipocytes. Leptin is a 16 kDa potent anorexigenic hormone produced
mainly by fat cells, It acts via its receptors in the central nervous system to reduce food
intake. Also, by using small interfering RNA treatment to knockdown the expression of
FFAR3 mRNA, it has been found that FFAR3 knockdown almost totally abolished the
ability of short chain fatty acids to induce leptin receptor expression and thus production
of leptin. These results suggested that FFAR3 has a potential role in the regulation of
feeding and obesity (Cherbut C et al. 1998; Cohen P et al. 2001).

5.7.1 FFAR4
FFAR4 is a deorphanized G protein coupled receptor. By using a receptor
internalization assay, medium to long chain free fatty acids were found to serve as
endogenous ligands (Fukunaga et al 2006). The saturated free fatty acids with a carbon
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length of 14 to 18 and unsaturated free fatty acids with a carbon length of 16 to 22 were
detected to activate FFAR4 (Hirasawa et al 2005).
5.7.2 Ligands. As mention above, FFAR4 is activated by medium to long chain
free fatty acids ligands. Although most fatty acids that were shown to activate FFAR4
were also able to activate FFAR1, the amino acids homology between both receptors was
only 10% (Hara T et al. 2013). Several pharmacological research reported a novel series
of FFAR4 agonists. NCG21 was developed as the selective agonist for FFAR4. Other
synthetic FFAR4 ligands have been reported recently, such as, TUG891, Compound 8
and Compound 9 (Hara T et al. 2011; Fujiwara K et al. 2005).
5.7.3 Expression. Expression of FFAR4 has been abundantly found in the
intestinal tract in both mice and human (Hirasawa et al 2005). FFAR4 is also expressed
in the intestinal endocrine cell line STC-1 (Hirasawa et al. 2005; Tanaka et al. 2008;
Miyauchi et al. 2009). Moreover, FFAR4 have been identified in adipocytes and
macrophages (Oh DY et al. 2010). Activation of the receptor increases glucose uptake
and adipogenesis in adipocytes cells whereas it exerted anti-inflammatory actions in
macrophages (Gotoh et al. 2007). Moreover, FFAR4 expression has been reported in
ghrelin cells and it may play a role in the lipid sensing cascade (Lu et al. 2012).
5.7.4 Signal Transduction and Physiological Function.

Studies in HEK293

cells have shown that both natural polyunsaturated fatty acids and synthetic ligands
mediated the release of intracellular calcium. However, they did not change the cAMP
production. FFAR4 is similar to FFAR1 is coupled to the Gq protein family. Moreover, it
has been reported that FFAR4 activation induces PI3 kinase.
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Hirasawa et al. used the STC-1 cell line to study the secretion of glucagon like
peptide (GLP-1). They found that fatty acids such as alpha linolenic acid,
docosahexaoienic acid, or palmitoleic acid activated FFAR4 to promote the release of
GLP-1 from the STC-1 (Dockray GJ 2003). Since FFAR1 is also expressed in STC-1,
they used small interfering RNA (siRNA) treatment to knockdown both receptors in order
to identify which receptor was being activated by fatty acids. The results showed that the
cells transfected with FFAR1 siRNA had no change in ability to release GLP-1 (Dockray
GJ 2003). However, there was a significant decrease in GLP-1 release detected in cells
transfected with FFAR4 siRNA. The ability of free fatty acids to cause release of GLP-1
by the activation of FFAR4 introduced a new insight for alternative strategy in the
treatment of diabetes (Hara T et al. 2011; Briscoe CP et al. 2006).

5.6.1 GPR84
GPR84 is a recently discovered G protein coupled receptor that is specifically
activated by medium chain free fatty acids, with carbon chain length of C9 to C14. (Wang
J et al 2006). In contrast, neither short nor long chain free fatty acid activated GPR84.
5.6.2 Ligands. GPR84 is activated by medium chain free fatty acids ligands. The
most potent ligand with that activate for GPR84 are: capric acid (C10:0), undecanoic acid
(C11:0), and lauric acid (C12:0) (Hirasawa A et al. 2008).
5.6.3 Expression and Physiological Function. Only few publications reported
on the function of GPR84. It is selectively expressed in peripheral blood leukocytes. In
addition, it has been reported that GPR84 is activated by medium chain free fatty acids
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and is coupled to Gi/o pathway (Wang J et al 2006). Studies have shown that in
monocytes/macrophages, medium chain fatty acids act via GPR84 to augment the
stimulation of IL-12 production by lipopolysaccharide. Therefore, GPR84 might have
important role in the free fatty acids metabolism to immune system regulation (Bouchard
C et al 2007).
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SIGNIFCANCE
The importance of chemosensing in the gut to regulate several physiological
functions is emerging with the advent of deorphanization of several G protein coupled
receptors (GPCRs) for free fatty acids. There are five distinct free fatty acid receptors
(FFAR1, FFAR2, FFAR3, GPR84, and FFAR4) that differ in ligand specificity, expression
pattern, and functional properties. Recent studies have shown that these receptors serve
as nutrient sensors and play an important role in a variety of physiological processes. In
the gastrointestinal tract they contribute to the secretion of regulatory peptides from
enteroendocrine cells. Therefore, free fatty acids are not only essential nutrients but also
extracellular signaling molecules.
Recent studies from our lab have shown that the release of brain-derived
neurotrophic factor (BDNF) from enteroendocrine cells in response to luminal stimulation
enhances the peristaltic reflex and gut motility. Release of BDNF from enteric glial cells
is important for neuronal survival. However, the specific FFA receptors types and the
signaling pathways involved in the release of paracrine agent is not known. In addition,
the role of FFA receptors in the expression of BDNF content from enteroendocrine cells
and enteric glial cells of the gastrointestinal tract is not known. In this context, we used
biochemical, molecular, and functional approaches to investigating the expression of FFA
receptors, their signaling pathway and their role in the regulation of BDNF content. The
knowledge we gained from this study will generate a better understanding the mechanism
by which FFA receptors works and the role of FFA receptors mediating BDNF. This can
also aid in the development of agonist which can help in the therapy of Gut motility
diseases.
21

HYPOTHESIS AND SPECIFIC AIMS

The following are the Specific Aims and underlying hypotheses.
Specific Aim 1:

To determine the expression of the free fatty acids receptors

(FFARs) in enteroendocrine cells (STC-1), glial cells, and in mouse intestinal cells.
Hypothesis. Receptors for free fatty acids are differentially expressed in
enteroendocrine cells and glial cells and in different regions of the gastrointestinal tract.

Specific Aim 2:

To determine the downstream signaling pathway involved in

long chain FFAR1 and FFAR4 in enteroendocrine cells (STC-1) and enteric glial cells.
Hypothesis. Signaling pathway of activated FFAR1 and FFAR4 in both STC-1
and enteric glial cells is mediated via stimulation of PLC/IP3/Ca+2 pathway.

Specific Aim 3:

To determine the role of long chain FFA receptors in the

regulation of brain derived neurotrophic factor content in STC-1 and enteric glial cells.
Hypothesis. Activation of FFAR1 and FFAR4 induces increase in BDNF content
in STC-1 and glial cells.
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CHAPTER 2
MATERIAL AND METHODS

2.1.1 Materials
Linolenic acid (LA) and GW9508 were obtained from Sigma-Aldrich (St Louis, Mo),
TUG891 was obtained from TOCRIS Bioscience (Bristol, UK) and GW1100 was obtained
from Cayman Chemical Company (Ann Arbor, MI). [35S] GTPγS, myo-[3H] inositol were
obtained from Perkin Elmer (Boston, MA); antibodies to FFAR1, FFAR2, FFAR3, ,
FFAR4, GPR84, , BDNF, GAPDH, β actin, GFAP, S100, Gαq, and Gα i1-3, were obtained
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); the BDNF Emax® ImmunoAssay
System was obtained from Promega Corporation (Promega Corporation, WI); U73122
(PLC inhibitor) was obtained from Calbiochem ( La Jolla, CA); Fura 2-AM, was obtained
from Invitrogen (Eugene, OR); western blotting, Dowex AG-1 X 8 resin (100-200 mesh
in format form), chromatography material and protein assay kit were obtained from BioRad Laboratories (Hercules, CA); RNAqueousTM kit was obtained from Ambion (Austin,
TX); PCR reagents were obtained from Applied Biosystems (Foster city, CA); SuperScript
MT II Reverse Transcriptase was obtained from Invitrogen (Carlsbad, CA); Dulbecco’s 25
modified Eagle’s medium (DMEM) was obtained from Fisher Scientific. Fluorescenceconjugated species-specific secondary antibody Alexa 488 and Alexa 594 were obtained
from Li-Cor (Lincoln, NE). siRNA FFAR1, siRNA FFAR4 and siRNA control were obtained
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). STC-1 cell line were obtained from
mouse musculus and enteric glial cells line were obtained from rat jejunum from ATCC.
All other chemical and reagents were obtained from Sigma (St Louis, MO).
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2.1.2 Tissue Collection
Wild type adult C57BL/6J mice were purchased from Jackson Laboratories (Bar
Harbor, ME). Animals were killed by CO2 inhalation/asphyxiation by placing them in
sealed chamber with a CO2 flow into the chamber at ~20% volume displacement per
minutes for ~ 5 minutes, Tissues (small intestine and colon) were immediately dissected
and used for immunohistochemistry. The animal was housed in the animal facility
administrated by the Division of Animal Resources, Virginia Commonwealth University.
All procedures were conducted in accordance with the Institutional Animal Care and Use
Committee of the Virginia Commonwealth University.

2.1.3 Expression of free fatty acid receptors (FFAR) in STC-1 and glial cells by RTPCR
Total RNA was isolated from both STC-1 and enteric glial cells with Ambion RNA
isolation kit. RNA from each preparation was reversely transcribed using the
SuperScript™ II system containing 50 mM Tris–HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2,
10 mM dithiothreitol (DTT), 0.5 mM deoxynucleoside triphosphates (dNTP), 2.5 μM
random hexamers and 200 units of reverse transcriptase in a 20 μl reaction volume. The
reactions were carried out at room temperature for 10 min at 37°C for 120 min, and
terminated by heating at 85°C for 5 min. Three μl of the reversely transcribed cDNA was
amplified in a final volume of 50 μl by PCR in standard conditions (2 mM MgCl 2, 200 μM
dNTP, 2.5 units Q5 High-Fidelity DNA Polymerase) with specific primers designed based
on rat and mouse cDNAs. PCR was performed for 35 cycles. For each experiment, a
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parallel control without reverse transcriptase was processed. The amplified PCR products
were analyzed on 1.5% agarose gel containing 0.1 μg/ml ethidium bromide.

2.1.4 Expression of FFAR1 and FFAR4 in STC-1 and glial cell by quantitative PCR
(qRT-PCR)
Quantitative PCR was performed using StepOne™ Real-Time PCR System
(Applied Biosystem, Foster city, CA) and the intercalating dye, SYBRgreen. For each
cDNA sample, real-time PCR was conducted in a 20 μl reaction volume containing
QuantitectTM SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). The following time
and temperature profiles were used for the real-time PCR reactions: 95 ˚C for 5 min; 50
cycles of a series consisting of 15 s at 94 ˚C, 30 s at 52 ˚C, 30 s at 72 ˚C; and a final
extension of 5 min at 72 ˚C. The optimal annealing temperatures were determined
empirically for each target and endogenous control (housekeeping gene) primer set.
Real-time PCR reactions were performed in triplicate. The fluorescent threshold value
was calculated using the StepOne™ Real-Time PCR System software. The absence of
peaks in water controls suggested a lack of primer-dimer formation.
Two general types of quantification strategies were performed in quantitative RTPCR (qRT-PCR). The levels of expressed genes were measured by an absolute
quantification or by a relative qRT-PCR. The absolute quantification approach relates the
PCR signal to input copy number using a calibration curve. Relative quantification relates
the PCR signal of the target transcript in a treatment group to that of another sample such
as an untreated control. Relative quantification of a target gene in relation to another gene
(reference gene or housekeeping gene) was calculated on the basis of delta delta CT
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values (CT, called as well CP), is the cycle number at which the fluorescence generated
within a reaction crosses the threshold. CT reflects the point during the reaction at which
a sufficient number of amplicons has accumulated). The target-gene expression is
Delta delta CT method ΔΔCT = (CT, Tag − CT, HKG) Treatment − (CT, Tag− CT, HKG) Control
Relative gene expression (Fold Change) = 2−ΔΔCT
Where, HKG is the housekeeping gene and Tag, the evaluated gene.
After normalization, the data for free fatty acid receptors were expressed as the foldchange in mRNA expression relative to that obtained from control samples.

2.1.5 Protein extraction
STC-1 and enteric glial cells were homogenized with solubilizing buffer of the
following composition, T-PER (tissue protein extraction reagent) plus protease and
phosphatase cocktail inhibitors. The supernatant was collected after sonication for 15
seconds and centrifugation at 10000g for 10 minutes at 4 °C. Then the protein
concentration was determined by DC protein assay kit from Bio-Rad (a colorimetric assay
to detect protein concentration after detergent solubilization based on Lowery assay).

2.1.6 Expression of free fatty acid receptors by Western blot
Equivalent amount of proteins were fractionated by SDS/PAGE electrophoresis
using 10% (w/v) acrylamide resolving gel and the separated proteins were
electrophoretically transferred onto a nitrocellulose membrane. The membrane was
blocked by incubation in 5% non-fat dried milk + Tris buffered saline with 0.1% tween-20
(TBST) for one hour at the room temperature. The membrane was incubated overnight

26

at 4 ˚C with various primary antibodies diluted in TBS-T 5% (w/v) non-fat dried milk (Table
2). The blots were washed three times for five minutes with TBS-T and then the
membrane was incubated with horseradish-peroxidase-conjugated to IRDye 800CW or
680 (LI-COR) corresponding secondary antibodies diluted to 1:20000 in 5% non-fat dry
milk + TBS-T for two hours with gentle shaking at room temperature. The membrane was
washed three times for five minutes with TBS-T, then the immunoreactive proteins were
visualized by using Super Signal Femto maximum sensitivity substrate kit (Pierce, IL).
Quantification of protein bands obtained on western blot was done using the
ODYSSEY infrared imaging system (LI-COR Biosciences). To maintain equal amount of
loaded proteins, the average intensity obtained of each band was normalized to its
respective band of β-actin. The average bands intensity were then presented as relative
fold changes compared with the control of the same lane.

2.1.7 Colocalization of free fatty acid receptors with BDNF in STC-1 and glial cells
by Immunocytochemistry
STC-1 or glial cells were cultured in 8-well chamber slide for two days and treated
with free fatty acid receptor agonists for 15 minutes. Cells were fixed in 4%
paraformaldehyde for 30 minutes at room temperature. After permeabilization with 0.3%
Triton X-100 for 5 minutes and blocking with 5% normal

donkey serum (Jackson

ImmunoResearch, PA) in PBS for 30 minutes (pH 7.4), cells were incubated with FFAR1
or FFAR4 antibodies along with BDNF antibodies for two hours at room temperature.
Cells were rinsed twice in PBS and then incubated with fluorochrome-conjugated
secondary antibodies Alexa 594 or 488 for one hour at room temperature. Cells were
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rinsed four times with PBS, then mounted with mounting buffer with DAPI on glass
microscope slides and analyzed under a Zeiss fluorescent photomicroscope.
Immunostaining in the absence of primary or secondary antibody was assessed for
background evaluation.

2.1.8 Histology and tissue Immunofluorescence
About 4 cm long pieces of mouse intestinal and colon samples were cleaned with
smooth muscle buffer of the following composition (NaCl 120 mM, KCl 4 mM, KH2PO4
2.6 mM, CaCl2 2.0 mM, MgCl2 0.6 mM, HEPES (N-2-hydroxyethylpiperazine-N’ 2ethanesulfonic acid) 25 mM, glucose 14 mM, and essential amino mixture 2.1% (pH 7.4).
and placed in 4% paraformaldehyde fixative solution overnight at 4 ˚C. After fixation the
tissue was placed on to pre-labeled tissue base mold, the entire tissue block was covered
with cryo-embedding media (OCT), and then stored in -80 ˚C. Then, cross sections (10
µm) were cut and mounted on gelatin-coated microscope slide. The slides were warmed
at 37 ˚C for one hour and then fixed with cold acetone for 10 minutes. The tissue were
blocked with blocking solution containing 3% of normal donkey serum in PBS. The slides
then were incubated with primary antibodies (1:200 dilution) diluted in PBS containing 5%
normal donkey serum at 4 ˚C overnight. After rinsing three times with 0.1% IHC-PBS, the
sections were incubated with fluorescence-conjugated species-specific secondary
antibody Alexa 488 for two hours at room temperature. Tissue sections were rinsed three
times in IHC-PBS with and without 0.1% tween-20. Then slides were mounted with
Citiflour antifadent mounting medium. Control sections were incubated without the
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primary antibody to evaluate nonspecific binding. Prepared slides were viewed with an
AxioCam Carl Zeiss microscope.

2.1.9. Assay for G protein activation
G proteins selectively coupled to FFAR1 and FFAR4 were identified from the increase
in G binding to the [35S] GTPS (5’-O-3-thiotriphosphate) using the method of Okamoto et al
2000. Ten ml of STC-1 or glial cells suspension (3 X 106 cells/ml) were homogenized in 20
mM HEPES medium (pH 7.4) containing 2 mM MgCl2, 1 mM EDTA and 2 mM DTT. After
centrifugation at 30,000 g for 15 min, the crude membranes were solubilized for 60 min at 4
C in 20 mM HEPES medium (pH 7.4) containing 2 mM EDTA, 240 NaCl, 0.5% CHAPS (3[(3-cholamidopropyl) dimethylammonio]-1-pro-panesulfonate), 2 mM PMSF, 20 μg/ml
aprotinin, and 20 μM leupetin. The membranes were incubated for 20 min at 37 C with 60
nM [35S] GTPS with 100 μM linolenic acid in the presence or absence of FFAR1 (GW1100,
10 μM) or FFAR4 (AH7614, 100 μM) antagonists in a solution containing 10 mM HEPES (pH
7.4), 100 M EDTA and 10 mM MgCl2. The reaction was terminated with 10 volumes of 100
mM of Tris-HCl medium (pH 8.0) containing 10 mM MgCl2, 10 mM NaCl and 10 M GTP, and
the mixture was placed in wells precoated with specific antibodies to Gq or Gi1-3. Coating
with G protein antibodies (1:1000) was done after the wells were first coated with anti-rabbit
IgG (1:1000) for two hours on ice. After incubation for two hours on ice, the wells were washed
three times with phosphate buffer saline solution (PBS) containing 0.05% Tween-20 followed
by solubilization with 0.1N NaOH and the radioactivity from each well was counted by liquid
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scintillation. The amount of [35S] GTPγS bound to the activated G subunit was expressed
as counts per minute (cpm).

2.1.10. Assay for phosphoinositide (PI) hydrolysis (PLC-β activity)
PI hydrolysis (PLC-β activity) was determined in STC-1 and glial cells by measuring
the formation of inositol phosphates using ion-exchange chromatography using the
method of Berridge et al as described previously (Murthy and Makhlouf 1991; Murthy,
Zhou et al. 2003). STC-1 and glial cells were labeled with [3H] myo-inositols (0.5 μCi/ml)
for 24 hours in inositol-free DMEM medium. The cultures were washed three times with
phosphate-buffer saline (PBS) and treated with long-chain free fatty acids receptor
agonists or antagonists; linolenic acid, GW9508, TUG891, GW1100, AH7614 or U73122
( PI hydrolysis inhibitor) for one minute. The reaction was terminated by the addition of
940 μl chloroform-methanol-HCl (50:100:1 v/v/v). After chloroform (310 μl) and water (310
μl) were added, the samples were vortexed and the phases were separated by
centrifugation at 3000 rpm for 20 minutes. The upper aqueous phase was applied to the
column containing 1 ml of 1:1 slurry of Dowex AG-1 X8 resin (100-200 mesh in formate
form) and distilled water.
The column was washed with 10 ml of water followed by 10 ml of 5 ml sodium
tetraborate-60 mM ammonium formate to remove [3H] glycerophosphoinositol. Total
inositol phosphates were eluted with 6 ml of 0.8 M ammonium formate-0.1 M formic acid.
The eluates were collected into scintillation vials and counted in gel phase after addition
of 10 ml of scintillant. The results were expressed as counts per minute.
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2.1.11 Measurement of [Ca2+]i
Free fatty acid receptor agonists-induced increase in [Ca2+]i was measured by
fluorescence in single STC-1 or glial cells loaded with fluorescent Ca2+ dye fura 2-AM.
STC-1 or glial cells were plated on coverslips for 12 h in DMEM. After being washed with
PBS, the cells were loaded with 5 µM fura 2-AM in HEPES containing 10% pluronic and
DMSO for 3 hours at room temperature. Clusters of cells were selected for imaging and
visualized. The cells were visualized through a 40 objective (ZEISS; 0.9 NA) with a Zeiss
Axioskop 2 plus upright fluorescence microscope and imaged with a setup consisting of
a charge coupled device camera (Imago, TILL Photonics, Applied Scientific
Instrumentation, Eugene, OR) attached to an image intensifier. The cells were
alternatively excited at 340 nm and 380 nm and the emitted light was detected using a
dichroic mirror (410 nm) and emission filter (530). The increase in

Ca2+

is related to an

increase in FIR (FIR= Fluorescence Intensity Ratio). The increase in intracellular calcium
in response to LA and FFAR1 (GW9508) and FFAR4 (TUG891) agonists was measured
by determining the ratio of the fluorescence of fura-2 AM at 340 and 380 nm excitation
(F340/F380).

2.1.12. Transfection of FFAR1 siRNA or FFAR4 siRNA
STC-1 or glial cells were plated in six-well plates and cultured until confluent. Antibiotic
free medium was used one day before the transfection. The cells were then transiently
transfected with the FFAR1 siRNA or FFAR4 siRNA by using Lipofectamine 2000 for 24 hours
according to the manufacturer’s instructions (Invitrogen). Briefly, 100 pmol of the siRNA in
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125 µl OptiMEM medium were mixed with 5 µl of Lipofectamine 2000 in 125 µl of Opti-MEM.
The mixture was incubated at room temperature for 20 min and added to wells containing 1.5
ml DMEM with 10% FBS for one day. The medium was then replaced with DMEM with 10%
FBS plus antibiotics for two days. Cells were maintained for a final 24 hours in DMEM without
FBS before experiments were started. Transfection efficiency was monitored by the
expression of the red fluorescence protein using FITC filters. Control cells were transfected
with vector alone. Analysis by psiREN DS-RED with fluorescence microscopy showed that
approximately 80-90%.of the cells were transfected.

2.1.13. Measurement of BDNF content by enzyme-linked immunosorbent assay
(ELISA)
STC-1 or glial cells were plated in 6 wells plate with DMEM containing 5% FBS
and antibiotics and cultured until 80-90% confluent. The cells were washed with DMEM
0 for 30 minutes. Cells were then treated for 15 minutes in DMEM 0 containing 1%
albumin, amastatin, and phosphoramidon with or without 100 µM linolenic acid, 10 µM
GW9508, 10 µM GW1100, 100 µM TUG891, or 100 µM AH7614. Cells were washed with
PBS and solubilized in Triton X-100 based lysis buffer plus protease and phosphatase
inhibitors. After centrifugation of the lysates at 14000 rpm for 10 minutes at 4 °C, the
protein concentration from the pellet were determined with a Dc protein assay kit from
Bio-Rad.
BDNF content in the STC-1 cells and glial cells was measured via a sandwich
ELISA using the Promega (Promega Corporation, WI) BDNF Emax immunoassay
according to the manufacturer’s directions. Polystyrene ELISA plates were coated with
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anti-BDNF mAb (1:1000) by adding 100 µl of the antibody to each well and overnight
incubation at 4 °C without shaking. The plate was vigorously washed on the next day with
TBST and blocked by adding 200 µl of block & sample 1X buffer to each well using a
multichannel pipettor and incubated for one hour at room temperature without shaking.
One hundred microliters of treated samples and BDNF standards were added in duplicate
and incubated with shaking for two hours at room temperature. The plate was washed for
five times and then incubated with 100 µl of anti-human BDNF pAb (1:500) at room
temperature for two hours with shaking. After five times washing of the plate with TBST,
100 µl of diluted anti-IgY HRP Conjugate (1:200) were added to each well and the plate
incubated for another two hours with shaking at room temperature. Then the plate was
washed five times and 100 µl of room-temperature TMB One solution (3,3′,5,5′tetramethylbenzidine), the substrate was added and incubated for 10 minutes with
shaking. One hundred microliters of 1N hydrochloric acid were added to wells to stop the
reaction. Then the plate was scanned using a plate reader and the absorbance was
measured at 450 nm within 30 minutes of stopping the reaction. The BDNF levels were
expressed as pg BDNF per mg total protein calculated from the standard curve.

Statistical Analysis

The results were expressed as means  SE and the experiments were performed
at least five times. Statistical significance was analyzed using Student’s t-test for paired
and unpaired values. The results were statistically analyzed using GraphPad Prism
software, San Diego, CA. A probability of P < 0.05 was considered significance.
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Table 1. Sequence of primers used for PCR, GAPDH; Glyceraldehyde 3-phosphate
dehydrogenase, -actin, FFAR: free fatty acid receptor, m:mouse, r:rat.

Size
Primer set

Forward Primer 5’  3’

Reverse Primer 3’  5’
(bp)

m/FFAR1

AATGCCTCCAATGTGGATAG

AGTCCTCGTCACACATATTG

159

m/FFAR3

TCCTGGCATCGGCTCACT

TGTAGGTTGCATTTCCCCAGTA

62

m/FFAR2

ACCAAATCACCTGCTATGAGAACTT

CACGGGCAGCACCACAT

58

m/GPR48

CCCCCTCTGGAATGTTTTTGT

TCGCATGCGTCAAAGC

63

m/FFAR4

GCATAGGAGAAATCTCATGG

GAGTTGGCAAACGTGAAGGC

335

r/β-actin

CAGGGTGTGATGGTGGGTATG

AGTTGGTGACAATGCCGTGTT

r/GAPDH

AAGGTGGTGAAGGAGGCGGC

GAGCAATGCCAGCCCCAGGA

r/FFAR1

ACTGGTCACTGGCTACTTGG

TTGGAGTCCTGGTCACACAT

65

r/FFAR3

GCAGTCTTTCCGTCATGCCT

TCCCTGAAGGTCTCTCCCAG

140

r/GPR84

AAGTGCATCGCAAGACTGGA

CTGAGGACGAAGCAAAGGAAC

156

r/FFAR4

AATCGCACCCACTTCCCTTT

GATGAGTCCCAGAACGGTGG

90

m/GAPDH

AGAAACCTGCCAAGTATGATG

GGAGTTGCTGTTGAAGTCG

122
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Table 2. Source and concentration of primary antibodies used and the product size
of the proteins identified

Product Size
Antibody

Company

Catalog #

Dilution
(kDa)

name

sc-32905

31

Santa Cruz

1:1000

FFAR3

sc-98332

39

Santa Cruz

1:1000

FFAR2

sc-32906

43

Santa Cruz

1:1000

GPR84

sc-99106

44

Santa Cruz

1:1000

FFAR4

sc-99105

52/42

Santa Cruz

1:1000

42

Sigma

1:1000

Promega

1:200

FFAR1

β-actin
BDNF

35

CHAPTER 3
RESULTS

3.1 Expression of Free Fatty Acid Receptors (FFARs)
Receptors for short-, medium- and long-chain free fatty acids (FFAs) belong to
relatively newly deorphanized G protein coupled receptor family and recent evidence
suggests that these receptors play a role in the regulation of gastrointestinal function such
as motility and secretion, and energy metabolism. FFARS are grouped according to the
chain length of FFAs that activate each FFARs. FFAR1 and FFAR4 are preferentially
activated by medium- and long-chain FFAs, but preferentially activated by long-chain
FFAs. FFA2 and FFA3 are activated by short-chain FFAs, whereas GPR84 is activated
by medium-chain, but not long-chain FFAs.
In the present study, we analyzed the mRNA and protein expression of FFAR1,
FFAR2, FFAR3, FFAR4 and GPR84 in mouse endocrine cells (STC-1 cells) and rat
enteric glial cells by RT-PCR, real time RT-PCR, and Western blot, and by
immunohistochemistry in mouse small intestine.

3.1A. Expression of FFAR1, FFAR2, FFAR3, FFAR4 and GPR84 mRNA in STC-1 and
Enteric Glial Cells
(i) RT-PCR. Primers for RT-PCR analysis of FFARs in STC-1 cells and glial cells
are based on rat FFARs sequences, The sequence of specific primers are listed in
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chapter 2 table 1.Messenger RNA for FFAR1 (159 bp), FFAR2 (58 bp), FFAR3 (62bP),
FFAR4 (335 bp) and GPR84 (63 bp) were detected by RT-PCR analysis of RNA isolated
from STC-1 cells (Figure 3). Under similar condition, mRNA for FFAR1 (65 bp), FFAR3
(114 bp), FFAR4 (90 bp) and GPR84 (156 bp) were detected by RT-PCR analysis of RNA
isolated from glial cells (Figure 4). The results suggest expression of all FFARs in both
enteroendocrine cells and enteric glial cells.
(ii) Real-time RT-PCR. For comparative analysis of FFARs in STC-1 and glial
cells, quantitative real time PCR was performed in triplicate in RNA isolated from both
STC-1 and enteric glial cells. Expression of FFAR4 was 5.3 fold higher compared to other
FFA receptors in STC-1 cells (Figure 5). In contrast, expression of FFAR1 was 2 fold
higher compared to FFAR4 in glial cells. (Figure 5). These results suggest differential
expression of FFAR1 and FFAR4 in in enteroendocrine and enteric glial cells.
3.1B. Expression of FFAR1 and FFAR4 protein in STC-1 and Glial Cells
Further confirmation for the differential expression of FFAR1 and FFAR4 in STC1 and glial cells was obtained using western blot analysis and specific antibodies to
FFAR1 and FFAR4. Expression of both FFAR1 (31 kDa) and FFAR4 (42 kDa) was
detected in homogenates prepared from STC-1 cells (Figure 6). Similarly expression of
both FFAR1 (31 kDa) and FFAR4 (42 kDa) was detected in homogenates prepared from
glial cells (Figure 7). For comparative analysis of FFAR1 and FFAR4 expression in STC1 and glial cells, densitometric analysis of FFARs normalized to loading control β-actin
was performed. Expression of FFAR4 was 1.62 fold higher compared to FFAR1 in STC1 cells. In contrast, expression of FFAR1 was 2.52 fold higher compared to FFAR4 in
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glial cells. The pattern of FFAR1 and FFAR4 protein expression is consistent with the
pattern of mRNA expression of these receptors in STC-1 and glial cells (Figure 8).
3.1C. Expression of FFAR1 and FFAR4 in Mouse Intestine
Immunohistochemical analysis of tissue cryosections obtained from mouse small
intestine shows the presence of FFAR1 and FFAR4 in specific cells of the mucosal layer
(Figure 7-11). FFAR1 and FFAR4 positive cells were located in the microvilli and crypts.
The cells were triangular in appearance and extended from the basal lamina to luminal
surface, typical of open type of enteroendocrine cells (EECs). Some FFAR1 and FFAR4
positive cells were located in close proximity to the intestinal epithelium, where enteric
glial cells are located (Figures 9 and 10). FFAR1 and FFAR4 were also present in the
core of the villi where subepithelial glial cells themselves are located. The
immunohistochemistry data confirmed expression of FFAR1 and FFAR4 in native
enteroendocrine cells and glial cells as well as the enteroendocrine cell line (STC-1) and
the glial cell line.
In summary, FFARs are differentially expressed in STC-1 versus glial cells with
predominant expression of FFAR4 in STC-1 cells and predominant expression of FFAR1
in glial cells.

Both FFAR1 and FFAR4 are also present in native enteroendocrine and

glial cells

3.2 Signaling Pathways Coupled to FFAR1 and FFAR4
After demonstrating differential expression of FFAR1 and FFAR4 in STC-1 and
glial cells, further studies were designed to examine the signaling pathways activated by
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these receptors in both STC-1 and glial cells. Activation of specific G protein(s) and
signaling pathways downstream of G proteins in response to the endogenous long chain
fatty acid, linolenic acid (100 µM), was measured. Since linolenic acid activates both
FFAR1 and FFAR4 receptors, agonist selective for FFAR1 (GW9508) and FFAR4
(TUG891), as well as antagonists selective for FFAR1 (GW1100) and FFAR4 (AH7614)
were used to analyze receptor-selective signaling pathways in both STC-1 and glial cell.

3.2A. Signaling in STC-1 Cells
(i) Identification of G proteins coupled to FFAR4. Studies in various tissue and
cell lines suggest that FFAR1 and FFAR4 are coupled to activation of G proteins (Salehi
et al. 2005 and Hirasawa et al. 2005), but the specific G protein coupled to FFAR4 in
enteroendocrine cells has not been identified. Membranes isolated from SCT-1 cells were
incubated with [35S]GTPγS (60 nM) in the presence or absence of linolenic acid (100 µM),
and FFAR1 or FFAR4 specific inhibitors were added to wells precoated with different Gα
antibodies. An increase in the binding of [35S] GTPγS complexed to specific Gα antibody
reflected the activation of the corresponding G protein. Incubation of membrane with
linolenic acid in the presence of GTPγS caused a significant increase in the binding of
[35S] GTPγS to Gαq (3967±253 cpm, P< 0.0001, n=6) (Figure 11). There was no increase
in the binding of [35S]GTPγS to wells coated with antibody to Gαi1-3 complex (Figure 12).
These results suggest that linolenic acid activates Gq, but not Gi proteins. Linolenic acidinduced increase in the binding of [35S]GTPγS to Gαq was blocked by a FFAR4 selective
antagonist (AH7614, 100 µM), but not by a FFAR1 selective antagonist (GW1100, 10 µM)
These results suggest that,

in STC-1 cells, long chain fatty acid linolenic acid
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preferentially activates FFAR4 receptors that are coupled to Gq.

The results are

consistent with the predominant expression of FFAR4 compared to FFAR1 in these cells.
(ii) Activation of PI hydrolysis. Previous studies (Kebeda et al. 2012 and Shah
et al. 2012) in various tissue and cell lines have shown that activation of FFA receptors
by polyunsaturated fatty acid resulted in stimulation of phosphoinositide (PI)-specific
phospholipase C (PLC-β) activity, and generation of inositol 1,4,5-trisphosphate (IP3).
However, to deduce the signaling pathway involved in activation of long chain free fatty
acid receptors in STC-1 cells, we measured the PLC activity in response to the long chain
fatty acid natural ligand linolenic acid (100 µM), FFAR4 selective agonist TUG891 (100
µM), and FFAR4 selective antagonist AH7614 (100 µM). Addition of linolenic acid to STC1 cells labeled with [3H]myo-inositol, caused a significant increase in PI hydrolysis,
measured as increase in water soluble [3H]inositol (410±40 cpm P<0.001, n=8). Similarly,
selective agonist for FFAR4 caused an increased in PI hydrolysis (332±81 cpm, n=8).
(Figure 13) Linolenic acid-induced increase in PI hydrolysis was significantly blocked by
the selective FFAR4 antagonist (AH7614, 100 µM) (183±15 cpm, P<0.001, n=8) (Figure
13). These results suggest that, In STC-1 cells linolenic acid-induced increase in PI
hydrolysis was mediated via FFAR4. The results are consistent with activation of Gq by
linolenic acid via FFAR4 in these cells.
(iii) Increase in intracellular calcium Activation of PLC-β results in the generation
of inositol 1,4,5-trisphosphate (IP3) and IP3-dependent Ca2+ release from intracellular
sarcoplasmic reticulum stores. We next examined the effect of linolenic acid and a
selective FFAR4 agonist (TUG891) on cytosolic Ca2+ ([Ca2+]i) by calcium imaging using
Fura-2 AM. An increase in F340/F380 fluorescence intensity ratio reflected an increase
40

in intracellular Ca2+. Consistent with the activation of PI hydrolysis, addition of linolenic
acid (100 µM) or TUG891 to STC-1 cells resulted in a rapid increase in cytosolic Ca2+ ,
n=40 (Figures 14 and 15).

3.2B Signaling in Glial Cells
(i) Identification of G proteins coupled to FFAR1. Studies in various tissue and
cells lines suggest that FFAR1 and FFAR4 are coupled to activation of G proteins, but
the specific G proteins coupled to FFAR1 in enteric glial cells have not been identified.
Membranes isolated from glial cells were incubated with [35S]GTPγS (60 nM) in the
presence or absence of linolenic acid, and FFAR1 or FFAR4 specific inhibitors and the
aliquots were added to wells precoated with different Gα antibodies; an increase in the
binding of [35S]GTPγS complexes to specific Gα antibody reflected the activation of the
corresponding G protein. Incubation of membrane with linolenic acid in the presence of
GTPγS caused a significant increase in the binding of [35S]GTPγS to Gαq (5097 cpm P<
0.001, n=6). (Figure 16). There was no increase in the binding of [35S]GTPγS to wells
coated with antibody to Gαi1-3 complex (Figure 17). These results suggest that linolenic
acid activates Gq, but not Gi proteins. Linolenic acid-induced increase in the binding of
[35S] GTPγS to Gαq was blocked by a FFAR1 selective antagonist (GW1100, 10 µM), but
not by a FFAR4 selective antagonist (AH7614, 100 µM). These results suggest that, in
glial cells, long chain fatty acid linolenic acid preferentially activates FFAR1 receptors that
are coupled to Gq. The results are consistent with the predominant expression of FFAR1
compared to FFAR4 in these cells.
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(ii) Activation of PI hydrolysis. To deduce the signaling pathway involved in
activation of FFAR1 in glial cells, we measured the PLC activity in response to long chain
fatty acid natural ligand 100 µM linolenic acid, FFAR1 selective agonist GW9508 10 µM,
and FFAR1 selective antagonist GW1100 10 µM. Addition of linolenic acid to glial cells
labeled with [3H]myo-inositol, caused a significant increase in PI hydrolysis, measured as
increase in water soluble [3H]inositol (3191 cpm, P<0.0001, n=8). (Figure 18) Similarly,
selective agonist for FFAR1 (GW9508, 10 µM) caused an increased in PI hydrolysis (2700
cpm n=8). Linolenic acid-induced increase in PI hydrolysis was significantly blocked by
the selective FFAR1 antagonist (GW1100, 10 µM) (1366 cpm, P<0.001, n=8), but not by
FFAR4 antagonist (AH7614, 100 µM)

(Figure 18). These results suggest that, in glial

cells, linolenic acid-induced increase in PI hydrolysis was mediated via FFAR1. The
results are consistent with activation of Gq by linolenic acid via FFAR1 in these cells.
Control studies showed that linolenic acid induced increase in PI hydrolysis was blocked
by the selective PLC inhibitor, U73122 (10 µM) (Figure 19).
(iii) Increase in intracellular calcium.

Activation of PLC-β results in the

generation of inositol 1,4,5-trisphosphate (IP3) and IP3-dependent Ca+2 release from
intracellular sarcoplasmic reticulum stores. We next examined the effect of linolenic acid
in the presence or absence of FFAR1 antagonist (GW1100, 100 µM) on cytosolic Ca+2
([Ca+2]i) by calcium imaging using Fura-2 AM. An increase in the fluorescence intensity
ratio (F340/F380) reflected an increase in intracellular Ca2+. Consistent with the activation
of PI hydrolysis, addition linolenic acid (50 µM and 100 µM) to glial cells resulted in a rapid
increase in cytosolic Ca+2 (Figure 20). The effect of linolenic acid was inhibited in the
presence GW1100 (Figure 21) suggesting that the effect of linolenic acid was mediated
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via activation of FFAR1. In support of this notion, a selective FFAR1 agonist GW9508
(100 µM) caused an increase in Ca2+ (Figure 22) n=40.
In summary, both FFAR1 and FFAR4 are coupled to Gαq and stimulation of PLCβ/IP3/ Ca+2 pathway. In enteroendocrine cells (STC-1) long chain fatty acids preferentially
activate FFAR4, whereas in glial cells long chain fatty acids preferentially activate FFAR1.
This is consistent with predominant expression of FFAR4 compared to FFAR1 in STC-1
cells, and predominant expression of FFAR1 compared to FFAR4 in glial cells.

3.3 Regulation of Brain-derived Neurotrophic Factor (BDNF) Content by Activation
of Long Chain FFAR in STC-1 and Enteric Glial Cells.
There are many hormones, neurotransmitters and neurotrophins that are released
in response to long chain free fatty acids in gastrointestinal tract. Activation of FFAR1
induces release of cholecystokinin (Elke Kaemmerer, 2010) and activation of FFAR4
activation induces release of incretin hormones (Frank Riemann, 2012). Of the several
neurotrophins identified, brain-derived neurotrophic factor (BDNF) has been associated
with regulation of gastrointestinal motility (Grider et al., 2006). However, the effect of long
chain free fatty acids on the BDNF content is not known. Several studies have been
addressed neurotrophins production using different approaches. In our study we used
mainly two approaches; in the first approach BDNF tagged with green fluorescent protein
was used to measure BDNF localization and expression in STC-1 and enteric glial cells,
and in the second approach enzyme-linked immunosorbent assay (ELISA) was used to
measure BDNF levels in the cell lysates.
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3.3A. Regulation of BDNF Levels by FFAR4 in STC-1 Cells
First we examined the colocalization of BDNF with FFAR4 in cultured STC-1 cells.
Some, but not all, cells show co-localization of BDNF with FFAR1 (Figure 23). Then, to
evaluate whether BDNF levels are regulated by activation of FFAR4, STC-1 cells were
treated for 15 minutes with linolenic acid (100 µM) and number of BDNF immunopositive
cells were counted.

As shown in Figure 24, treatment of cells with linolenic acid

significantly increased the number of BDNF positive cell (four folds increase compared to
control cells) (P<0.0001).
The immunocytochemistry study results were further confirmed by the
measurement of BDNF content by ELISA. Linolenic acid (100 µM) caused a significant
increase in BDNF (P< 0.01, n=7) (Figure 25). The increase was blocked by selective
FFAR4 antagonist (AH7614, 100 µM), but not by a selective FFAR1 antagonist (GW1100,
10 µM), suggesting that, in STC-1 cells, linolenic acid selectively activates FFAR4 to
increase BDNF levels. This conclusion was further supported by siRNA approach to
suppress FFAR4 expression. As shown in Figure 26, linolenic acid-induced increase in
BDNF levels was abolished in cells expressing FFAR4 siRNA. The selective involvement
of FFAR4 receptors in the regulation of BDNF in STC-1 cells is consistent with the
predominant expression of FFAR4 in these cells and selective activation of Gq/PLC/Ca2+
pathway coupled to FFAR4 by linolenic acid.
.3.3B. Regulation of BDNF Levels by FFAR1 in Glial Cells
First we examined the colocalization of BDNF with FFAR4 in glial cells. Some, but
not all cells show co-localization of BDNF with FFAR1 (Figure 27). Then, to evaluate
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whether BDNF levels are regulated by the activation of FFAR1, glial cells were treated
for 15 minutes with linolenic acid (100 µM) and the number of BDNF immunopositive cells
were counted. As shown in Figure 28, treatment of cells with linolenic acid significantly
increased the number of BDNF positive cell (2.5 fold increase compared to control cells)
(P<0.0001).
The immunocytochemistry study results were further confirmed by the
measurement of BDNF content by ELISA. Linolenic acid (100 µM) caused a significant
increase in BDNF (P< 0.01, n=7) (Figure 29). The increase was blocked by a selective
FFAR1 antagonist (GW1100, 10 µM), but not by a selective FFAR4 antagonist (AH7614,
100 µM), suggesting that, in contrast to STC-1 cells, in glial cell linolenic acid selectively
activates FFAR1 to increase BDNF levels. This conclusion was further supported by
siRNA approach to suppress FFAR1 expression. As shown in Figure 30, linolenic acidinduced increase in BDNF levels was abolished in cells expressing FFAR1 siRNA. The
selective involvement of FFAR1 receptors in the regulation of BDNF in glial cells is
consistent with the predominant expression of FFAR1 in these cells and selective
activation of Gq/PLC/Ca2+ pathway coupled to FFAR1 by linolenic acid.
In summary, in enteroendocrine cells (STC-1), long chain fatty acids increase
BDNF content via FFAR4, whereas in glial cells they increase BDNF content via FFAR1.
This is consistent with predominant expression FFAR4 and preferential activation of
FFAR4 by long chain fatty acids in STC-1 cells and predominant expression of FFAR1
and preferential activation of FFAR1 in in glial cells.
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Figure 1. Cell lines used in this study.
Photomicrographs of mouse STC-1 cells (enteroendocrine cell line) and rat glial cells
(enteric glial line) in culture.

46

Figure 2. Immunohistochemical staining of glial cell markers.
Enteric glial cells were stained for glial cells markers, glial fibrillary acidic protein (GFAP,
right panel) and S100 (left panel). Middle panel: Control staining without primary antibody
Magnification 20X.

GFAP

Control
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S100

Figure 3. Messenger RNA expression of free fatty acid receptors (FFARs) in STC-1
cells.
Total RNA isolated from mouse STC-1 cells was reverse transcribed using 2 µg of total
RNA using qScript cDNA preparation kit. The cDNA was amplified with specific primers
for FFAR1, FFAR2, FFAR3, FFAR4, and GPR84 and analyzed on 2% agarose gel
containing ethidium bromide. The sequence of primers are listed in Table 1. PCR
products of expected size were obtained with primers for FFAR1 (159 bp), FFAR2 (58bp),
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FFAR3 (62 bp), GPR84 (63 bp), and FFAR4 (335 bp).

Figure 4. Messenger RNA expression of free fatty acid receptors (FFARs) in glial
cells.
Total RNA isolated from rat enteric glial cells was reverse transcribed using 2 µg of total
RNA using qScript cDNA preparation kit. The cDNA was amplified with specific primers
for FFAR1, FFAR3, FFAR4, and GPR84 and analyzed on 2% agarose gel containing
ethidium bromide. The sequence of primers are listed in Table 1. PCR products of
expected size were obtained with primers for FFAR1 (65 bp), FFAR3 (114 bp), GPR84
(115 bp), and FFAR4 (90 bp).
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Figure 5. Quantitative PCR (qRT-PCR) of free fatty acid receptors in mouse STC-1
and rat glial cells.
Quantitative PCR was conducted in a 20 µl of reaction volume containing Quantitect
™SYBRgreen PCR Mastermix. Real-time PCR reactions were performed in triplicate.
Results were expressed as fold change or fold differences in FFARs after normalizing
with endogenous control, GAPDH or β-actin. Right panel: Expression in glial cell. GPR84
and FFAR4 expression levels with references to FFAR1 after normalizing with
endogenous control, GAPDH or β-actin. Left panel: Expression in STC-1 cells. FFAR2,
FFAR3, FFRA4 and GPR84 expression levels with references to FFAR1. Expression of
FFAR1 is higher in enteric glial cells compared to other FFARs whereas expression of
FFAR4 is higher in STC-1 cells compared to other FFARs. Values represent the means
±SEM of 4 separate experiments. In glial cells FFAR4 and GPR84 *p<0.05 vs FFAR1
**p<0.001 vs FFAR1.
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Figure 6. Protein expression of free fatty acid receptors (FFARs) in STC-1 cells.
Cell lysates obtained from cultured mouse STC-1 cells. Equal amounts of total proteins
were separated with SDS-PAGE and expression of FFAR1 and FFAR4 was analyzed by
western blot using receptor-specific antibodies. β-actin was used as loading control.
Protein band of expected size for both FFAR1 (31 kDa) and FFAR4 (42 kDa) was
detected by western blot analysis.
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Figure 7. Protein expression of free fatty acid receptors (FFARs) in glial cells.
Cell lysates obtained from cultured rat glial cells. Equal amounts of total proteins were
separated with SDS-PAGE and expression of FFAR1 and FFAR4 was analyzed by
western blot using receptor-specific antibodies. β-actin was used as loading control.
Protein band of expected size for both FFAR1 (31 kDa) and FFAR4 (42 kDa) was
detected by western blot analysis.
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Figure 8. Comparitive quantitative analysis FFAR1 and FFAR4 expression in STC1 and glail cells.
Densitometric analysis of the western blot of FFAR1 and FFRA4 expression Right panel:
Relative abundance of FFAR4 compared with FFAR1 protein expression in STC-1. Left
panel: Relative abundance of FFAR1 in glial cells compared with FFAR4 protein
expression. **P< 0.001 vs FFAR1
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Figure 9. Expression of FFAR1 in mouse small intestine by Immunohistochemistry.
Cryosections of mouse small intestine was stained with FFAR1 antibody and imaged at
40x magnification. Some cells contained within submucosal epithelium area where
enteric glial cells located are also positive for FFAR1. FFAR1-positive cells are located
within mucosa of intestinal crypt. Arrows pointed to FFAR1 positively stained cells.
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Figure

10.

Expression

of

FFAR4

in

mouse

small

intestine

by

Immunohistochemistry.
Cryosections of mouse small intestine was stained with FFAR4 antibody and imaged at
40x magnification. FFAR4-positive cells are located within mucosal of colonic crypt with
enteroendocrine cell-like morphology.

Some cells contained within submucosal

epithelium area where enteric glial cells located are also positive for FFAR4. Arrows
pointed to FFAR4 positively stained cells.
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Figure 11. Activation of Gq protein by linolenic acid via FFAR4 in STC-1 cells.
Membranes isolated from STC-1 cells were incubated for 30 minutes at 37 C with [35S]
GTPS and 100 µM linolenic acid (LA) in the presence or absence of antagonist for
FFAR1 (GW1100, 10 µM) or FFAR4 (AH7614, 100 µM). Aliquots quantity amount of
protein were added to the wells precoated with the specific antibody to Gα q. The amount
of radioactivity bound to activate Gαq was measured by liquid scintillation and expressed
as counts per minutes (cpm). Linolenic acid (LA) caused a significant increase in the
binding of [35S] GTPS-Gαq that was blocked by the selective FFAR4, but not FFAR1,
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Figure 12. Effect of linolenic acid on the activation of Gi protein in STC-1 cells.
Membranes isolated from STC-1 cells were incubated for 30 minutes at 37 C with [35S]
GTPS and 100 µM linolenic acid (LA) in the presence or absence of antagonist for
FFAR1 (GW1100, 10 µM) or FFAR4 (AH7614, 100 µM). Aliquots of equal amounts of
protein were added to the wells pre-coated with the antibody to Gαi1-3 and incubated for
two hours. The amount of radioactivity bound to activate Gαi1-3 was measured by liquid
scintillation and expressed as counts per minute (cpm). Treatment with LA had no effect
on the binding of [35S] GTPS-Gαi1-3 Values are expressed as mean ± SEM of 6
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Figure 13. Activation of PI hydrolysis by linolenic acid (LA) via FFAR4 in STC-1
cells.
Cultured mice STC-1 cells were labeled with myo-[3H] inositol for 24 hours and then
treated with LA (100 µM), FFAR4 agonist TUG891 (100 µM), or FFAR4 antagonist
AH7614 (100 µM). PI hydrolysis was measured as increase in water soluble [3H] inositol
by ion exchange chromatography. Result are expressed as count per minute. Treatment
of cells with LA caused a significant increase in PI hydrolysis and the increase was
blocked by the FFAR4 antagonist.

FFAR4 agonist also caused an increase in PI

hydrolysis. Values are expressed as mean ± SEM of 8 experiments. **P< 0.001; *p<0.01
significant increase in PI hydrolysis with LA vs. basal.
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Figure 14. Increase in intracellular calcium by linolenic acid (LA) in STC-1 cells.
Cultured mouse STC-1 cells were loaded with fluorescent Ca2+ dye fura 2-AM (5 µM) in
in HEPES buffer containing 10% pluronic and DMSO for 3 hours at room temperature.
Clusters of cells were selected for imaging and visualization. The cells were alternatively
excited at 340 nm and 380 nm and the increase in cytosolic calcium in response to
linolenic acid was measured as the increase in the ratio of the fluorescence of fura-2 at
F340/F380 nm emission at 530 nm. Representative results demonstrated that addition of
LA to STC-1 cells resulted in a rapid increase in cytosolic Ca2+.
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Figure 15. Increase in intracellular calcium by FFAR4 agonist TUG891 in STC-1
cells.
Cultured mouse STC-1 cells were loaded with fluorescent Ca2+ dye fura 2-AM (5 µM) in
in HEPES buffer containing 10% pluronic and DMSO for 3 hours at room temperature.
Clusters of cells were selected for imaging and visualization. The cells were alternatively
excited at 340 nm and 380 nm and the increase in cytosolic calcium in response to FFAR4
agonist, TUG891 (100 µM) was measured as the increase in the ratio of the fluorescence
of fura-2 at F340/F380 nm emission at 510 nm. Representative results demonstrated that
addition of TUG891 resulted in a rapid increase in cytosolic Ca2+.
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Figure 16. Activation of Gq protein by linolenic acid via FFAR1 in glial cells.
Membranes isolated from enteric glial cells were incubated for 30 minutes at 37 C with
[35S] GTPS and 100 µM linolenic acid (LA) in the presence or absence of antagonist for
FFAR1 (GW1100, 10 µM) or FFAR4 (AH7614, 100 µM). Aliquots of equal amounts of
protein were added to the wells pre-coated with the specific antibody to Gαq. The amount
of radioactivity bound to activated Gαq was measured by liquid scintillation and expressed
as counts per minute (cpm). Linolenic acid caused a significant increase in the binding
of [35S] GTPS-Gαq and the increase in the binding was blocked by the selective FFAR1,
but not FFAR4, antagonist. Values are expressed as mean ± SEM of 6 experiments.
**P<0.001 vs basal.

6000

Gα-[35S] GTPγS binding (cpm)

**
**
4000

2000

0

Basal

LA

FFAR1
FFAR4
antagonist antagonist

Gαq Activation

61

Figure 17. Effect of linolenic acid on the activation of Gi protein in glial cells.
Membranes isolated from glial cells were incubated for 30 minutes at 37 C with [35S]
GTPS and 100 µM linolenic acid (LA) in the presence or absence of antagonist for
FFAR1 (GW1100, 10 µM) or FFAR4 (AH7614, 100 µM). Aliquots quantity equal amounts
of protein were added to the wells precoated with the antibody to Gαi1-3 and incubated for
two hours. The amount of radioactivity bound to activated Gα i1-3 measured by liquid
scintillation and expressed as counts per minutes (cpm). Treatment with LA had not effect
on the binding of [35S] GTPS-Gαi1-3 Values are expressed as mean ± SEM of 6
experiments.
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Figure 18. Activation of PI hydrolysis by linolenic acid (LA) via FFAR1 in glial cells.
Cultured glial cells were labeled with myo-[3H] inositol for 24 hours and then treated with
LA (100 µM) in the presence or absence of FFAR1 antagonist (GW100, 10 µM) or FFAR4
antagonist (AH7614, 100µM), or FFAR1 agonist GW9508 (10 µM).

PI hydrolysis was

measured as increase in water soluble [3H]inositol by ion exchange chromatography.
Result are expressed as count per minute (cpm). Linolenic acid caused a significant
increase in PI hydrolysis and the increase was blocked by the FFAR1 antagonist, but not
FFAR4 antagonist. FFAR1 agonist also caused an increase in PI hydrolysis. Values are
expressed as mean ± SEM of 8 experiments. **P< 0.001; *P<0.01 significant increase in
PI hydrolysis with LA vs basal.
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Figure 19. Inhibition of linolenic acid-induced PI hydrolysis by non-specifc PLC
inhibitor U73122 enteric glial cells.
Cultured glial cells were labeled with myo-[3H] inositol for 24 hours and then treated with
linolenic acid (LA, 100 µM) in the presence or absence of PLC inhibitor U73122 (10 µM).
PI hydrolysis was measured as increase in water soluble [3H] inositol by ion exchange
chromatography. Result are expressed as count per minute. Treatment of cells with LA
caused a significant increase in PI hydrolysis and the increase was blocked by U73122.
Values are expressed as mean ± SEM of 8 experiments. **P< 0.001 significant increase
in PI hydrolysis with LA vs basal.
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Figure 20. Increase in intracellular calcium by linolenic acid (LA) in glial cells.
Cultured glial cells were loaded with fluorescent Ca2+ dye fura 2-AM (5 µM) in in HEPES
buffer containing 10% pluronic and DMSO for 3 hours at room temperature. Clusters of
cells were selected for imaging and visualization. The cells were alternatively excited at
340 nm and 380 nm and the increase in cytosolic calcium in response to linolenic acid
was measured as the increase in the fluorescence intensity ratio of fura-2 at F340/F380
nm emission. Representative results demonstrated that addition of LA to glia cells
resulted in a rapid increase in cytosolic Ca2+.
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Figure 21. Inhibition of linolenic acid-induced Increase in calcium by FFAR1
antagonist in glial cells.
Cultured glial cells were loaded with fluorescent Ca2+ dye fura 2-AM (5 µM) in in HEPES
buffer containing 10% pluronic and DMSO for 3 hours at room temperature. Clusters of
cells were selected for imaging and visualization. The cells were alternatively excited at
340 nm and 380 nm and the increase in cytosolic calcium in response to linolenic acid in
the presence or absence of FFAR1 antagonist GW1100 (10 µM) was measured as the
increase in the fluorescence intensity ratio F340/F380 nm emission. Representative mean
results of 40 cells demonstrated that addition of LA to glial cells resulted in a rapid
increase in cytosolic Ca2+.n=40.
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Figure 22. Increase in intracellular calcium by FFAR1 agonist, GW9508 in glial cells.
Cultured glial cells were loaded with fluorescent Ca2+ dye fura 2-AM (5 µM) in in HEPES
buffer containing 10% pluronic and DMSO for 3 hours at room temperature. Clusters of
cells were selected for imaging and visualization. The cells were alternatively excited at
340 nm and 380 nm and the increase in cytosolic calcium in response to FFAR1 agonist
GW9508 (100 µM) acid was measured as the increase in the fluorescence intensity ratio
at F340/F380 nm emission. Representative mean results of 40 cells demonstrated that
addition of FFAR1 agonist to glial cells resulted in a rapid increase in cytosolic Ca2+.
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Figure 23. Colocalization of FFAR4 and BDNF in cultured mouse STC-1 cells.
Cultured STC-1 cells were stained with primary antibody to BDNF or FFAR4 and
secondary antibody Flexa 488 (green) for BDNF and Flexa 594 (red) for FFAR4. The cells
were imaged at x400 magnification. Arrows point to the cells colocalization of BDNF and
FFAR4. Left panel: Cells stained with nuclear stain dapi.
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Figure 24. Increase in BDNF positive cells by linolenic acid in STC-1 cells.
Cultured STC-1 cells were stained with BDNF antibody before and after treatment with
linolenic acid (100 µM) for 15 min. The cells were imaged at x400 magnification. Results
demonstrated an increase in BDNF (green fluorescence) after linolenic acid (LA)
treatment. Right panel: Quantitative analysis of BDNF positive cells before and after
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Figure 25. Increase in BDNF content by linolenic acid via FFAR4 in STC-1 cells.
Cultured STC-1 cells treated with 100 µM linolenic acid (LA) in the presence or absence
of FFAR4 antagonist (AH7614, 100 µM) or FFAR4 agonist (TUG891, 100 µM) for 15 at
37°C. The amount of BDNF in the cell lysates was measured by ELISA. Linolenic acidinduced increase in BDNF content was inhibited by FFAR4-antagonist. Values are
expressed as mean ± SEM of 3 experiments. *P< 0.05 significant increase of BDNF
versus control.
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Figure 26. Increase in BDNF content by linolenic acid via FFAR4 in STC-1 cells.
Cultured STC-1 cells were transfected with control siRNA for FFAR4 siRNA for 48 h and
treated with 100 µM linolenic acid (LA) or FFAR4 agonist (TUG891, 100 µM) for 15 at
37°C. The amount of BDNF in the cell lysates was measured by ELISA. Linolenic acid or
FFAR4 agonist caused an increase in BDNF content in cells transfected with control
siRNA but not in cells transfected with FFAR4 siRNA. . Values are expressed as mean ±
SEM of 3 experiments. *P< 0.05 significant increase of BDNF versus basal. #P< 0.05
significant inhibition of BDNF vs basal. Inset showing transfection of pSIREN-DNRDsRed vector verified by immunofluorescence
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Figure 27. Colocalization of FFAR1 and BDNF in cultured enteric glial cells.
Cultured glial cells were stained with primary antibody to BDNF for FFAR1 and secondary
antibody Flexa 488 (green) for BDNF and Flexa 594 (red) for FFAR1. The cells were
imaged at x400 magnification. Arrows point to the cells colocalization BDNF and FFAR1.
Right panel: cells stained with nuclear staining dapi.
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Figure 28. Increase in BDNF positive cells by linolenic acid in glial cells.
Cultured glial cells were stained with BDNF antibody before and after treatment with
linolenic acid (100 µM) for 15 min. The cells were imaged at x400 magnification. Results
demonstrated an increase in BDNF (green fluorescence) after linolenic acid (LA)
treatment. Right panel: Quantitative analysis of BDNF positive cells before and after
treatment with linolenic acid *P < 0.0001 versus control.
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Figure 29. Increase in BDNF content by linolenic acid via FFAR1 in glial cells.
Cultured glial cells treated with 100 µM linolenic acid (LA) in the presence or absence of
FFAR1 antagonist (GW1100, 10 µM) or FFAR1 agonist (GW9508, 10 µM) for 15 at 37°C.
The amount of BDNF in the cell lysates was measured by ELISA. Linolenic acid-induced
increase in BDNF content was inhibited by FFAR1. Values are expressed as mean ± SEM
of 3 experiments. *P< 0.05 significant increase of BDNF versus basal.
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Figure 30. Increase in BDNF content by linolenic acid via FFAR1 in glial cells.
Cultured glial cells were transfected with control siRNA or FFAR1 siRNA for 48 h and
treated with 100 µM linolenic acid (LA) for 15 at 37°C. The amount of BDNF in the cell
lysates was measured by ELISA. Linolenic acid caused an increase in BDNF content in
cells transfected with control siRNA but not in cells transfected with FFAR1 siRNA. .
Values are expressed as mean ± SEM of 3 experiments. *P< 0.05 significant increase of
BDNF versus basal. #P< 0.05 significant inhibition of BDNF vs basal. Inset showing
transfection of pSIREN-DNR-DsRed verified by immunofluorescence
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DISCUSSION

Free fatty acids are essential dietary components that contribute to various cellular
functions, provide energy to the cell, supply building material for cellular structure
including membrane and organelles, and regulate cellular metabolism in various
physiological and pathophysiological conditions. As mentioned in the first chapter, short
chain fatty acids (SCFAs) are produced during fermentation of resistant starches and
indigestible fiber by anaerobic gut flora, while long chain fatty acids are generated from
dietary intake, lipolysis in adipose tissue, and hepatic forms of neutral fats, cholesteryl
esters and phospholipids.
A series of experiments demonstrated that individual fatty acids have different
effects in the nutrient sensing, gastrointestinal motility, hormone/paracrine release and
function. For example, administration of the SCFA propionate (C3) caused decreased
food intake in sheep (Masahito O and Michael A, 2003). Butyrate (C4), at physiological
concentration of 10 to 30 mM, increased the proximal colon contraction, while acetate
(C2) and propionate (C3) at the same concentration decreased proximal colon
contraction, thus decreased the motility (Hurst et al 2014). Long chain fatty acids have
been reported to play an important role in the regulation of insulin secretion in the
pancreatic β-cells, in bone inflammation, and omega 3 restrain bone loss (Fabien CJ et
al. 2013). However, chronic consumption of high fat diet has been attributed to the
development of several diseases such as Type II Diabetes and obesity. Until the last
decade, the roles of fatty acids were thought to be mediated exclusively through actions
on cellular metabolism.
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In recent years, characterization and deorphanization of some seven
transmembrane G-protein coupled receptors (GPCRs) by the identification of FFA ligands
has provided a new development of the mechanism of action of free fatty acids. They
serve as not only nutrients and metabolic substrates but also as extracellular signaling
molecules.
Upon digestion of food, the gastrointestinal tract represents the first site of
interaction between ingested nutrients and the host. The dietary fat and fatty acids are
sensed via binding to specific free fatty acids receptors that are expressed on the surface
of a variety of epithelial cells in the gut that mediate the release of gut peptides. It has
been reported that ingested fat induces secretion of gut hormones; CCK from specialized
enteroendocrine cells, I-cells, glucagon-like peptides and peptide YY from L cells, and
glucose-dependent insulinotropic peptide from L cells (Liddle RA 1997, Strader AD et al.
2005 and Sternini C et al. 2008). Cholecystokinin (CCK) the upper small intestinal
hormone is one of the primary endocrine regulators of small intestinal digestion. It was
first described as a satiety hormone that plays a role in stimulation of pancreatic secretion,
inhibition of gastric motility and food intake (Dockray GJ .2003).
In 2008 Toshiki Tanaka group has been using α-linolenic acid as a long chain free
fatty acid to examine the role of free fatty acid receptors in secretion of CCK in vitro. They
have demonstrated that long chain FFAs enhance the CCK secretion in STC-1 cells that
mainly occurs through FFAR4.
Moreover, it has been reported that the secretion of GLP-1 from STC-1 is
mediated via the activation of FFAR4 (Hirasawa et al. 2005). GLP-1 is a gut hormone is
released from L cells and has a pivotal role in mediating food stimulated glucose
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dependent secretion of insulin from pancreatic β cells. Also, GLP-1 has a role in
stimulating β cells proliferation and differentiation. GLP-1 is considered the most potent
insulinotropic incretin. Therefore, identification of FFAR4-mediating GLP-1 release
induced by FFAs is very important in the treatment of diabetes. In addition, a number of
studies have provided evidence for the importance of FFAR1 and FFAR4 in potentiating
glucose stimulated insulin secretion via the secretion of GLP-1 and GIP hormones from
enteroendocrine cells (Itoh et al 2003, Efdalk et al 2008).
Furthermore, FFAR2 and FFAR3 have been shown to stimulate the release of PYY
(Kennedy RL et al, 2010). PYY is a neuroendocrine mediator is secreted from
enteroendocrine cells (L cells) and plays a role in slow gastric emptying and stimulates
digestion and nutrient absorption in the small intestine.
Most studies have focused on the role of free fatty acid receptors in energy intake,
and regulating gastric and intestinal hormone/paracrine release and function. Little is
known of the presence of free fatty acids receptors in the endocrine cell and enteric glial
cells in the gut, and their role in regulation of brain derived neurotrophic factor. We
hypothesize that free fatty acid receptors play a role in the regulation of brain-derived
neurotrophic factor levels in the enteric glial and endocrine cells. Therefore, we examined
1) FFAR1, FFAR2, FFAR3, FFAR4 and GPR84 expressions in enteroendocrine cells,
glial cells and in mouse mucosal cells, 2) the signaling pathway involved in long chain
free fatty acid receptors FFAR1 and FFAR4 in enteroendocrine cells (STC-1) and enteric
glial cells, 3) the role of FFAR1 and FFAR4 in the regulation of brain derived neurotrophic
factor contents in STC-1 and enteric glial cells.
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Expression of FFARs in Enteroendocrine Cell and Enteric Glial Cells
In this study, we firstly reported that mRNA levels for FFAR1, FFAR2, FFAR3,
FFAR4 and GPR84 are expressed differentially in enteroendocrine cell line STC-1 and
enteric glial cells. Among several tissues and cell types in different species, various FFA
receptor gene have been demonstrated. Our data showed an abundant expression of
FFAR1 mRNA in enteric glial cells with two fold more expression than FFAR4 and GPR84.
The study from Briscoe et al 2003 and Kotarsky et al 2003 revealed expression of FFAR1
in the skeletal muscle, liver and heart. TaqMan quantitative PCR showed that FFAR1
mRNA is predominantly expressed in insulin producing β cells (Itoh et al. 2003). Other
studies have detected FFAR1 expression in the pancreatic β cell line MIN6, mouse βTC3, and rat insulinoma INS-1E cells (Sharipo H et al. 2005). It was also detected in non βcells, such as, human breast cancer cell line MCF-7 and enteroendocrine cells
(Yonezawa T et al. 2004).
Furthermore, we have demonstrated the expression of FFAR2 mRNA in the
enteroendocrine cell line STC-1. Other studies also have detected the level of FFAR2
mRNA in variety of tissues and cell types; such as neutrophils (Brown et al. 2003), skeletal
muscle and heart (Nilsson et al, 2003), adipose tissue (Hong et al. 2005). FFAR2 has
also been detected in the breast cancer cell line, MCF-7 (Yonezawa et al. 2006) and in
rat distal ileum and colon (Karaki et al. 2006). We also reported the expression of other
SCFA receptors such as FFAR3 mRNA in the enteroendocrine cells and enteric glial cells.
Initial studies done on FFAR3 reported highest level of mRNA expression in adipose
tissue (Brown et al. 2003). The expression was also seen in 3T3-L1 and 3T2-F442A
adipose cell line (Xiong et al. 2004).
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Our results and of others have shown FFAR4 mRNA expression was found in
mouse STC-1 cells. Our studies demonstrated abundant expression of FFAR4 in STC-1
cells compared with other FFA receptors. This is in contrast to the abundant expression
of FFAR1 compared to FFAR4 in enteric glial cells (Figure 5). Although the ligand profiles
were similar for FFAR1 and FFAR4, both receptors were activated by long chain fatty
acids, however, the amino acid homology between both receptors was only 10% (Hara T
et al. 2009). Consistent with our data, FFAR4 was found to be expressed in the mouse
intestinal tract with abundant expression in the murine enteroendocrine STC-1 cells
(Hirasawa et al. 2005, Gotoh C et al. 2007, and Miyauchi et al. 2009).
Furthermore, in our studies the medium chain free fatty acid receptor, GPR84
mRNA was expressed in both enteroendocrine cells and enteric glial cells. Other studies
have shown the expression of GPR84 in various tissues such as heart, lung, liver, and
leucocytes. In particular, inflammatory cells, granulocytes, T and B cells also express
GPR84 (Yousefi B et al. 2001; Venkataraman and Kuo 2005).
Consistent with differential expression of mRNA levels of FFAR1 and FFAR4 in
our STC-1 and glial cells, results from protein expression showed the same distribution
and differential expression. FFAR1 protein level was higher in enteric glial cells while
FFAR4 protein level was more in STC-1 cells (Figure 8). Taken together, our expression
results suggest that there is a different role and mechanism of each FFA receptors in
different cells. Thus, we examined the signal transduction of long chain FFAR1 in enteric
glial cells and FFAR4 in STC-1 cells.
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Signaling Mechanisms Downstream of FFAR1 and FFAR4
This is the first study to demonstrate the effects of long chain fatty acids (linolenic
acid) on enteric glial cells. Our studies demonstrate that FFAR1 are coupled to pertussis
toxin (PTx)-insensitive Gq protein (Figure 16). FFAR1 activation caused an increase in
PLC-β activity (PI hydrolysis) in enteric glial cells (Figure 18). Moreover, calcium release
in response to linolenic acid and FFAR1 agonist was decreased with administration of
FFAR1 antagonist (Figure 20-22). Several studies on the mechanism of activation FFAR1
via long chain fatty acid have been reported that FFAR1 is coupled to the G protein
subunit Gαq, and leads to release of intracellular calcium (Fuijwara et al. 2005; Mancini
AD and Poitout V 2013). Our studies provided a more detailed analysis of the signaling
pathways and demonstrated for the first time that long chain fatty acids initiate signaling
pathway via FFAR1 in enteric glial cells.
On the other hand, our studies demonstrate that activation of FFAR4 in
enteroendocrine cells via long chain fatty acid linolenic acid leads to activation of the
Gq/PLC-β/Ca2+ pathway. These conclusion were reached through several lines of
evidence: (1) Abundance expression of FFAR4 in STC-1 cells (Figure 5 and 8), (2)
selective activation of Gq and stimulation of PI hydrolysis (Figure 13). (3) Calcium release
in response to linolenic acid and FFAR4 agonist (Figure 14 and 15). These data are
consistent with previous studies that showed FFAR4 expression in HEK293 cells is
coupled to Gq and promotes elevation of intracellular calcium. It is noteworthy, that in the
preset study, we used linolenic acid, a natural agonist of long chain FFA receptors that
can activate both FFAR1 and FFAR4.
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Taken together, our studies imply that both FFAR1 and FFAR4 are coupled to Gαq
that stimulates of PLC-β/IP3/ Ca+2 pathway. In enteroendocrine cells (STC-1) long chain
fatty acids preferentially activates FFAR4, whereas in glial cells long chain fatty acids
preferentially activates FFAR1. This is consistent with the predominant expression of
FFAR4 compared to FFAR1 in STC-1 cells, and predominant expression of FFAR1
relative to FFAR4 in glial cells.

Regulation of Brain-derived Neurotrophic Factor (BDNF) Content by FFAR1 and
FFAR4 in STC-1 and Enteric Glial Cells
The discovery of FFAR1 and FFAR4 in the epithelial layer of the gastrointestinal
tract has expanded the field of intraluminal nutrient sensing. Upon ingestion of food,
chemosensory cells scattered throughout the gastrointestinal tract make direct contact
with the gut lumen and their activation triggers the release of gastrointestinal regulatory
peptides, neurotransmitters and neurotrophins. One of those is brain derived neurotrophic
factor (BDNF).
As outlined in the introduction, BDNF is a neurotrophin present in the intestine
where it participates in the survival and growth of enteric neurons, and stimulation of
intestinal peristaltic reflexes and propulsion (Alqudah M et al. 2015). The physiological
role of BDNF in the peristaltic reflex has been examined in genetically modified mouse.
Mouse deficient in BDNF (BDNF+/-) which have reduced peristalsis, release of 5-HT and
slower velocity of propulsion of fecal pellets compared with wild type BDNF+/+ mice (Goggi
J et al. 2002 and Grider et al. 2006). Furthermore, BDNF release in the gut has been
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demonstrated from mucosal enteroendocrine cells and from intrinsic primary afferent
neurons innervating the mucosa of rat and mouse colon in response to mucosal
mechanical stimulation (Grider et al. 2006). Within this context, the role of BDNF is to
augment release of 5-HT and CGRP, thereby augmenting peristaltic reflex leading to
enhanced propulsive motility (Grider et al. 2006).
Beside the motility effect of BDNF, the localization of BDNF in enteric neurons
suggests that BDNF may acts as neurotransmitter or neuromodulator in the gut, similar
to the notion of BDNF in the central nervous system. BDNF could be secreted from enteric
neurons and can activate the release of CGRP in an autocrine manner, or it could be
secreted from mucosal cells and act in a paracrine manner. Three different groups have
identified BDNF in the glial cells and in endothelial cells (Lucini C et al, 2002, and
Lommatzch M et al, 1999).
In the present study, we have demonstrated the colocalization of BDNF with the
FFAR4 in the STC-1 cells (Figure 23) and colocalization of BDNF with the FFAR1 in the
glial cells (Figure 27).
It is not known whether BDNF content level is regulated by the long chain free fatty
acids via FFAR1 and FFAR4. The present study has demonstrated the functional role of
activated FFAR1 and FFAR4 in BDNF regulation in both STC-1 and glial cells. The series
of experiments demonstrated that the natural agonist, long chain fatty acid, linolenic acid,
administration caused an increase in BDNF content level in STC-1 via FFAR4. The
increase in BDNF in response to linolenic acid was demonstrated by both
immunocytochemistry and measurements of BDNF by ELISA. The specific role of FFAR4
in the regulation of BDNF levels in STC-1 cells was demonstrated using both
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pharmacological and molecular approaches. A selective FFAR4 antagonist, but not the
FFAR1 antagonist, and silencing FFAR4 expression blocked the effect of LA on BDNF
(Figures 25 and 26). Linolenic acid also caused an increase in BDNF content in glial
cells.

Increase in BDNF in response to linolenic acid was demonstrated by both

immunocytochemistry and measurements of BDNF by ELISA. The specific role of FFAR1
in the regulation of BDNF levels in glial cells was demonstrated using both
pharmacological and molecular approaches. A selective FFAR1 antagonist, but not the
FFAR4 antagonist, and silencing FFAR1 expression blocked the effect of LA on BDNF
(Figures 29 and 30). These results are consistent with the predominant expression of
FFAR4 and selective activation of FFAR4 by linolenic acid in STC-1 cells, and with the
predominant expression of FFAR1 and selective activation of FFAR1 by linolenic acid in
glial cells.
In conclusion, the presented findings indicate the cell-specific expression of FFARs
in STC-1 cells and glial cells, and their colocalization with BDNF, and the role of FFARS
in the regulation of BDNF levels. Given the importance of enteroendocrine cells and glial
cells as well as BDNF in the regulation of motility, secretion and energy metabolism, our
studies underscore the physiological importance of free fatty acids and their receptors
regulation of gastrointestinal functions. Our results potential suggest new therapeutics
as FFARs to targets involved in gastrointestinal disorders.
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